<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67381</article-id><article-id pub-id-type="doi">10.7554/eLife.67381</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Permeant fluorescent probes visualize the activation of SARM1 and uncover an anti-neurodegenerative drug candidate</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-227621"><name><surname>Li</surname><given-names>Wan Hua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3881-5796</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227578"><name><surname>Huang</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227579"><name><surname>Cai</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227580"><name><surname>Wang</surname><given-names>Qian Wen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227581"><name><surname>Zhu</surname><given-names>Wen Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227582"><name><surname>Hou</surname><given-names>Yun Nan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227583"><name><surname>Wang</surname><given-names>Sujing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227584"><name><surname>Cao</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227585"><name><surname>Zhao</surname><given-names>Zhi Ying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227586"><name><surname>Xie</surname><given-names>Xu Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227589"><name><surname>Du</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-227587"><name><surname>Lee</surname><given-names>Chi-Sing</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3564-8224</contrib-id><email>cslee-chem@hkbu.edu.hk</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-227588"><name><surname>Lee</surname><given-names>Hon Cheung</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6993-0121</contrib-id><email>leehoncheung@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-220074"><name><surname>Zhang</surname><given-names>Hongmin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4356-3615</contrib-id><email>zhanghm@sustech.edu.cn</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-225848"><name><surname>Zhao</surname><given-names>Yong Juan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4564-1912</contrib-id><email>zhaoyongjuan@cuhk.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Ciechanover Institute of Precision and Regenerative Medicine, School of Life and Health Sciences, The Chinese University of Hong Kong</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Department of Chemistry, Hong Kong Baptist University, Kowloon Tong</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Department of Biology, Southern University of Science and Technology</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution>Kobilka Institute of Innovative Drug Discovery, School of Life and Health Sciences, The Chinese University of Hong Kong</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lin</surname><given-names>Hening</given-names></name><role>Reviewing Editor</role><aff><institution>Cornell University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Marletta</surname><given-names>Michael A</given-names></name><role>Senior Editor</role><aff><institution>University of California, Berkeley</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>04</day><month>05</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67381</elocation-id><history><date date-type="received" iso-8601-date="2021-02-09"><day>09</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-05-02"><day>02</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Li et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67381-v2.pdf"/><abstract><p>SARM1 regulates axonal degeneration through its NAD-metabolizing activity and is a drug target for neurodegenerative disorders. We designed and synthesized fluorescent conjugates of styryl derivative with pyridine to serve as substrates of SARM1, which exhibited large red shifts after conversion. With the conjugates, SARM1 activation was visualized in live cells following elevation of endogenous NMN or treatment with a cell-permeant NMN-analog. In neurons, imaging documented mouse SARM1 activation preceded vincristine-induced axonal degeneration by hours. Library screening identified a derivative of nisoldipine (NSDP) as a covalent inhibitor of SARM1 that reacted with the cysteines, especially Cys311 in its ARM domain and blocked its NMN-activation, protecting axons from degeneration. The Cryo-EM structure showed that SARM1 was locked into an inactive conformation by the inhibitor, uncovering a potential neuroprotective mechanism of dihydropyridines.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARM1</kwd><kwd>fluorescent probes</kwd><kwd>base-exchange</kwd><kwd>allosteric inhibitors</kwd><kwd>CryoEM structure</kwd><kwd>covalent inhibitors</kwd><kwd>cADPR</kwd><kwd>NAD</kwd><kwd>NAADP</kwd><kwd>dHNN</kwd><kwd>nisoldipine</kwd><kwd>CD38</kwd><kwd>cyclic ADP-ribose</kwd><kwd>ADP-ribosyl cyclase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Ministry of Science and Technology of the People's Republic of China</institution></institution-wrap></funding-source><award-id>2019YFA0906000</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Hongmin</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>31871401</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Yong Juan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001747</institution-id><institution>Hong Kong Baptist University</institution></institution-wrap></funding-source><award-id>RC-SGT2/18-19/SCI/005</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Chi-Sing</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001747</institution-id><institution>Hong Kong Baptist University</institution></institution-wrap></funding-source><award-id>RC-ICRS-18-19-01A</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Chi-Sing</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The first-in-class cell-permeant fluorescent probe provides direct and visual evidence of SARM1 activation in axonal degeneration and identified the first covalent, allosteric inhibitor of SARM1 acting on the NAD-binding pocket in the ARM domain.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Axon degeneration (AxD) occurs in most neurodegenerative disorders (<xref ref-type="bibr" rid="bib4">Coleman and Höke, 2020</xref>). Sterile Alpha and TIR Motif–containing 1 (SARM1) acts as a main effector in this process (<xref ref-type="bibr" rid="bib31">Osterloh et al., 2012</xref>) and its depletion significantly attenuates AxD (<xref ref-type="bibr" rid="bib11">Geisler et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Osterloh et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Turkiew et al., 2017</xref>). SARM1 controls AxD through its enzymatic activity (<xref ref-type="bibr" rid="bib6">Essuman et al., 2017</xref>). It is self-inhibitory and is activated by nicotinamide mononucleotide (NMN) (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>), resulting in depletion of the intracellular NAD-pool (<xref ref-type="bibr" rid="bib6">Essuman et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). However, recent studies suggest that nicotinamide adenine dinucleotide (NAD) itself is an inhibitor of SARM1 activation and the balance between NMN and NAD controls the activation of SARM1 (<xref ref-type="bibr" rid="bib8">Figley et al., 2021</xref>; <xref ref-type="bibr" rid="bib18">Jiang et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Sporny et al., 2020</xref>).</p><p>It should be noted that SARM1 is not just a simple NADase activated to deplete the cellular NAD. We have documented that SARM1 is a multifunctional enzyme with properties similar to CD38, a universal signaling enzyme possessing not only NADase activity but also catalyzing both the cyclization of NAD to cyclic ADP-ribose (cADPR) and the exchange of nicotinamide in NADP with nicotinic acid to produce nicotinic acid adenine dinucleotide phosphate (NAADP) (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). Both cADPR and NAADP are messengers regulating calcium mobilization in the endoplasmic reticulum and the endo-lysosomes, respectively (reviewed in <xref ref-type="bibr" rid="bib10">Galione, 1994</xref>; <xref ref-type="bibr" rid="bib21">Lee, 2012</xref>; <xref ref-type="bibr" rid="bib23">Lee and Zhao, 2019</xref>). The catalytic similarities and its ubiquitous presence in non-neuronal cells suggest that SARM1 may be a calcium signaling enzyme as well.</p><p>Since SARM1 is important in axon degeneration and potentially other physiological processes as well, we thus aim to design and synthesize probes for visualizing SARM1 activation in live cells and to screen drug library for potent inhibitors.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Probe design, synthesis, and characterization</title><p>We focused on its base-exchange reaction for designing specific probes for SARM1 and had shown that pyridyl derivatives can readily serve as substrates (<xref ref-type="bibr" rid="bib14">Graeff et al., 2006</xref>; <xref ref-type="bibr" rid="bib22">Lee and Aarhus, 1997</xref>). We thus conjugated various styryl derivatives to pyridine to produce a series of conjugates (PCs) as fluorescent probes for SARM1 activity (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We reasoned that conjugating the electron-rich styryl derivative with pyridine should provide a donor-π-acceptor framework (<xref ref-type="bibr" rid="bib32">Pawlicki et al., 2009</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). The positive charge of the pyridinium moiety of the product should delocalize over the conjugated π-system and lead to fluorescence changes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Pyridine conjugates (PC1-9, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11A</xref>) were synthesized using the Pd-catalyzed cross-coupling strategy with yields ranging from 33.5 to 85.0%. The synthesis details are in the 'Materials and methods' section and product characterizations are shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2</xref>–<xref ref-type="fig" rid="fig1s10">10</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Design and characterization of PC probes.</title><p>(<bold>A</bold>) Strategy of fluorescent imaging of the activated SARM1. (<bold>B</bold>) Designing based on pyridine and styryl derivatives with a donor-π-acceptor framework. (<bold>C</bold>) Structure of PC6. (<bold>D</bold>) The kinetics of the fluorescence increase at the maximal absorbance wavelengths catalyzed by SARM1-dN, in the presence of 100 μM NMN, 100 μM NAD, and 50 μM PCs. (<bold>E</bold>) Time-dependent changes of the emission spectra at the isosbestic point (350 nm). (<bold>F</bold>) HPLC analysis of PC6 reaction. Red line: in the presence of PC6, NMN, and NAD; Gray line: without PC6. Insert: MS analysis and structure of PAD6. (<bold>G</bold>) Absorbance and fluorescence spectra of 25 μM PC6/PAD6. (<bold>H</bold>) Emission spectra with dose of NMN (10, 20, 40, 60 μM) in the presence of NAD, PC6, and SARM1-dN. Inset: the initial rates plotted to NMN concentrations. (<bold>I</bold>) Emission spectra with doses of SARM1-dN in the presence of NMN, NAD, and PC6; Inset: the initial rate plotted to SARM1 concentrations. (<bold>J</bold>) The reaction rates of 10 μM PC6, in the presence of 100 μM NMN and 100 μM NAD, compared with NAD analogss (100 μM) catalyzed by SARM1. (<bold>K</bold>) The reaction rates of 10 μM PC6 catalyzed by SARM1, NADase, and CD38. PC = pyridine conjugate, NMN = nicotinamide mononucleotide.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig1">Figure 1D-K</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig1-data1-v2.xlsx"/></supplementary-material> </p><p> <supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplements 11C, 12</xref> and <xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig1-data2-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Synthetic scheme of PC1–PC9. PC = pyridine conjugate.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC1</bold> in DMSO-<italic>d</italic><sub>6</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC2</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC3</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC4</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp5-v2.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC5</bold> in DMSO-<italic>d</italic><sub>6</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp6-v2.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC6</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp7-v2.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 8.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC7</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp8-v2.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 9.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC8</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp9-v2.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 10.</label><caption><title><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of <bold>PC9</bold> in CDCl<sub>3</sub>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp10-v2.tif"/></fig><fig id="fig1s11" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 11.</label><caption><title>Structures of PC1–9 and activity screening.</title><p>(<bold>A</bold>) Chemical structures of PC1–9. (<bold>B</bold>) Quantification of SARM1-dN. SARM1-dN was pulled down by the BC2 nanobody (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>) conjugated beads, which efficiency was close to 100%. The purified SARM1-dN proteins were supplied to SDS-PAGE and Coomassie blue staining. The protein contents of SARM1-dN were calculated with a standard curve of BSA after intensity scanning. (<bold>C</bold>) The initial rates of the fluorescence increase at the maximal absorbance/emission wavelengths (PC5: 400 nm/530 nm; PC6: 390 nm/520 nm; PC7: 340 nm/445 nm; PC8: 375 nm/490 nm) catalyzed by SARM1-dN, in the presence of NMN, NAD, and PCs. PC = pyridine conjugate, NMN = nicotinamide mononucleotide.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp11-v2.tif"/></fig><fig id="fig1s12" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 12.</label><caption><title>UV-vis absorption spectra scanning of the reactants.</title><p>The reactants of 50 μM PCs and 100 μM NAD during the 50 min reactions catalyzed by the activated SARM1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp12-v2.tif"/></fig><fig id="fig1s13" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 13.</label><caption><title>Fluorescence spectra of the reactants.</title><p>The reactants of 50 μM PCs and 100 μM NAD during the 50 min reactions catalyzed by the activated SARM1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig1-figsupp13-v2.tif"/></fig></fig-group><p>The PC probes were tested using a recombinant SARM1 with the N-terminal mitochondrial-localizing peptide truncated, SARM1-dN (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>) (described in <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11B</xref>), with NAD as the acceptor of base-exchange and NMN as an activator. As shown in <xref ref-type="fig" rid="fig1s12">Figure 1—figure supplement 12</xref>, significant shifts in UV-vis spectra were observed in the reactions with the oxygenated derivatives (PC5-8, <italic>O</italic>-series), but not the nitrogenated derivatives (PC1–4, <italic>N</italic>-series), nor PC9 with diene as linker. The emission spectra of the reactive <italic>O</italic>-series showed steady increase as the reaction progressed (<xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>, spectra; <xref ref-type="fig" rid="fig1">Figure 1D</xref>, kinetics; <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11C</xref>, initial rate), with PC6, the chemical structure shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>, exhibiting the largest fluorescence increase (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><p>The time course study for the reaction involving PC6 showed that the UV absorption decreases at 330 nm but increases at 400 nm with an isosbestic point at 350 nm (<xref ref-type="fig" rid="fig1s12">Figure 1—figure supplement 12</xref>; <xref ref-type="fig" rid="fig1">Figure 1E</xref>). Corresponding to the absorbance change was the red shift in the fluorescence spectra, from the emission maximum at 430 nm of PC6 to 520 nm of PAD6 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>The conversion of PC6 to the exchange product, PAD6, was verified by purifying it using HPLC and characterized by high resolution mass spectrometry (HRMS) (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The remarkably large spectral changes are anticipated from our design, as the pyridine ring becomes positively charged after its exchange into NAD (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, inlet), a much stronger electron acceptor in the D−π−A structure, thereby increasing intramolecular charge transfer and shifting the emission maximum by over 100 nm. The conversion-induced spectral changes were consistent with the spectra of the HPLC-purified products, PAD6 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><p>The observed spectral changes showed a linear dependence on NMN, with as low as 10 μM being effective (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), confirming that SARM1 is an auto-inhibitory enzyme activated by NMN (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). The fluorescence increase was also proportional to the amount of NMN-activated SARM1 (<xref ref-type="fig" rid="fig1">Figure 1I</xref>), with a detection limit of 48 ng/mL. As an in vitro assay for SARM1, PC6 provides more than 100-fold higher sensitivity over other commonly used probes, such as εNAD, NGD, or NHD (<xref ref-type="fig" rid="fig1">Figure 1J</xref>).</p><p>In addition to sensitivity, PC6 also shows exquisite selectivity toward SARM1 versus CD38 and <italic>N. crassa</italic> NADase (<xref ref-type="bibr" rid="bib13">Graeff et al., 1994</xref>). All three possess NADase activity as detected by εNAD (<xref ref-type="fig" rid="fig1">Figure 1K</xref>), but only SARM1 could produce large fluorescence increase with PC6.</p></sec><sec id="s2-2"><title>Imaging SARM1 activation in live cells</title><p>PC6 was added to HEK293 cells overexpressing either wildtype SARM1 or the enzymatically inactive mutant, E642A (<xref ref-type="bibr" rid="bib6">Essuman et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Green fluorescence was clearly seen evenly distributed in the whole cells in the wildtype, but not in the mutant cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), indicating active SARM1 was required. Intracellular production of PAD6 was confirmed in extracts of wildtype but not the E642A cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). CZ-48, a cell-permeant mimetic of NMN and activator of SARM1 (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>), dramatically increased the PAD6 fluorescence (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, right column) and none in E642A-cells. These results indicate that PC6 is cell-permeant and can be exchanged into the cytosolic NAD by the activated SARM1 to produce PAD6 having a large red shift in fluorescence. PAD6 was also cell-impermeant because of its charged ADP-ribose moiety and accumulated in the cytosol, greatly increased its detection sensitivity in live cells.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Live-cell imaging of SARM1 activation.</title><p>(<bold>A</bold>) Western blot of the overexpression of SARM1 and inactive mutant, E642A in HEK293 cells. (<bold>B</bold>) Confocal fluorescence images of cells in (<bold>A</bold>) after incubation with PC6 in presence or absence of CZ-48. Green: PAD6; red: ConA-Alex-647; (<bold>C</bold>) HPLC and MS analysis of PAD6 from SARM1-OE cells. The metabolites were extracted by 0.6 M PCA from the cells in (<bold>A</bold>) after treating with 50 μM PC6 for 24 hr. Inset: MS analysis. (<bold>D</bold>) Confocal images of wildtype, or <italic>SARM1</italic>-KO HEK293T cells with PC6 in presence or absence of CZ-48. (<bold>E</bold>) The HEK293 cells carrying the inducible SARM1 were incubated with 50 μM PC6 in presence or absence of 0.5 mg/mL Dox and/or 100 μM CZ-48. The PAD6 fluorescence was analyzed by flow cytometry. (<bold>F</bold>) Confocal images of <italic>NMNAT1</italic>-KO/HEK293 T cells, incubated with PC6. Cell edges were marked according to the bright-field images. (<bold>G</bold>) Quantification of the cell fluorescence in (<bold>F</bold>). All the above experiments were repeated at least three times (means ± SDs; n = 3; Student’s <italic>t-</italic>test, *p&lt;0.05; **p&lt;0.01, ****p&lt;0.0001). Scale bar 10 μm.</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig2">Figure 2E and G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig2-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Expression level of SARM1 for <xref ref-type="fig" rid="fig2">Figure 2E</xref> and the activities of CD38.</title><p>(<bold>A</bold>) Western blots analysis of the expression of SARM1 in the inducible cell lines with or without treatment of 0.5 μg/mL Dox and 100 μM CZ-48 for the indicated time. (<bold>B</bold>) The HEK293T cells overexpressing wildtype and Type III mutant CD38 (mutCD38) (<xref ref-type="bibr" rid="bib25">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Zhao et al., 2012</xref>) were incubated with 50 μM PC6 for the indicated time and the fluorescence of PAD6 was analyzed in the flow cytometry. (<bold>C</bold>) The cellular cADPR levels in the cells (<bold>A</bold>) were measured by the cycling assay (<xref ref-type="bibr" rid="bib15">Graeff and Lee, 2002</xref>). PC = pyridine conjugate, cADPR = cyclic ADP-ribose.</p><p> <supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B and C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig2-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig2-figsupp1-v2.tif"/></fig></fig-group><p>PC6 also could detect the activity of SARM1 endogenously expressed in HEK293T cells (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). CZ-48 activated the endogenous SARM1 and produced increase of cytosolic PAD6 signal (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, upper right), but none in the SARM1-knockout cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, right lower), confirming the specificity of PC6 for SARM1.</p><p>An HEK293 cell line carrying doxycycline (Dox)-inducible SARM1 (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>) was used to further substantiate that the PAD6 fluorescence was derived from SARM1 activity. Without induction, only basal SARM1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) with minimal activity was detected (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, green dots), while activated by CZ-48, resulting in increase in PAD6-fluorescence (orange triangles). Induction of SARM1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) produced minimal signal also (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, purple squares), confirming SARM1 is auto-inhibitory. With CZ-48, both the basal and the induced SARM1 were activated, resulting in the largest signal (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, black triangles). In <italic>SARM1</italic>-knockout cells, no signal was detected (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <italic>SARM1</italic>-KO; <xref ref-type="fig" rid="fig2">Figure 2E</xref>, blue and red dots).</p><p>Endogenous NMN can be increased by ablating NMN-adenylytransferase (NMNAT1) (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>) to activate SARM1. Correspondingly, <italic>NMNAT1</italic> knockout in HEK293T cells also resulted in increasing PAD6 fluorescence (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) in a time-dependent manner (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><p>Consistent with the in vitro results showing that PC6 is highly selective for SARM1 over CD38 in live cells, cells expressing either wildtype or Type III mutant CD38 (<xref ref-type="bibr" rid="bib25">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Zhao et al., 2012</xref>) did not show PAD6-signal after 48 hr incubation with PC6 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), even though the expressed enzymes readily increased cellular cADPR (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p></sec><sec id="s2-3"><title>Imaging SARM1 activation during AxD</title><p>Vincristine (VCR)-induced AxD in peripheral neuropathy is a common side effect of chemotherapy (<xref ref-type="bibr" rid="bib6">Essuman et al., 2017</xref>) and is thought to be due to SARM1-activation (<xref ref-type="bibr" rid="bib12">Gerdts et al., 2013</xref>). Mouse dorsal root ganglion (DRG) neurons were infected with lentivirus carrying TdTomato for visualizing the axons (<xref ref-type="fig" rid="fig3">Figure 3A and C</xref>, orange), and with either a non-targeting (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) or <italic>Sarm1</italic>-specific shRNA (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In the non-targeting group, VCR elevated PAD6-fluorescence (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, green), indicating activation of SARM1, by as early as 4–8 hr and reaching a maximum by 16 hr (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref>, blue). AxD started at about 20 hr (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, blue; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), temporally consistent with a causal role for SARM1. Another measure of SARM1 activation is the elevation of cellular cADPR (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>), which occurred (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, blue) by 12 hr, peaking at 24 hr. Neurons not treated with VCR showed neither SARM1-activation nor AxD (<xref ref-type="fig" rid="fig3">Figure 3A,D,E,F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, CTRL).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>SARM1 activation in mouse DRG upon vincristine treatment.</title><p>(<bold>A, C</bold>) Confocal imaging of SARM1 activation in DRG neuronal axons. The neurons were infected with virus expressing TdTomato to provide easy imaging of the axons. Cells were additionally transfected with either scramble (<bold>A</bold>) or <italic>Sarm1</italic>-specific (<bold>C</bold>) shRNAs and treated with 50 μM PC6, 200 μM CZ-48, or 50 nM Vincristine and imaged in the indicated time points. Green: PAD6; orange: TdTomato; scale bar 50 μm. (<bold>B</bold>) Knockdown efficiency of <italic>Sarm1</italic>. Scr, scramble shRNA; KD, <italic>Sarm1</italic>-specific shRNA. (<bold>D</bold>) Quantification of the fluorescence intensity of PAD6 in DRGs. (<bold>E</bold>) Intracellular cADPR contents. (<bold>F</bold>) Indices of AxD. All the above experiments were repeated at least three times (means ± SDs; n = 3; Student’s <italic>t-</italic>test, ***p&lt;0.001; ****p&lt;0.0001). AxD = axon degeneration, cADPR = cyclic ADP-ribose, PC = pyridine conjugate, VCR = Vincristine.</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig3">Figure 3B, D-F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig3-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Integrity of axons visualized by the TdTomato fluorescence.</title><p>The DRG neurons, on div6, were infected with the lentivirus expressing TdTomato and scramble shRNA (<bold>A</bold>) or <italic>Sarm1</italic>-specific shRNA (<bold>B</bold>) and three days later, incubated with 50 nM VCR or 200 μM CZ-48 with 50 μM PC6. The photos of axons with TdTomato fluorescence were captured under the confocal microscope (Nikon, A1). Scale bar 50 μm. VCR = Vincristine.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Reducing endogenous SARM1 using shRNA (<xref ref-type="fig" rid="fig3">Figure 3B,D and F</xref>, KD) reduced the PAD6 fluorescence without altering its peaking at 16 hr (<xref ref-type="fig" rid="fig3">Figure 3C</xref>; 3<italic>D</italic>, KD +VCR) and reduced AxD (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, KD +VCR; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), further substantiating a causal role for SARM1. CZ-48 induced SARM1-activation more rapidly (<xref ref-type="fig" rid="fig3">Figure 3A and D</xref>, red) and elevated cADPR higher (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, red), confirming its direct action. Intriguingly, CZ-48 did not induce massive AxD as VCR (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, CZ-48; S5<italic>A</italic>). These results indicate SARM1-activation is a necessary and causal factor, but not a sufficient one for AxD. Other critical factors and downstream events of microtubular dysfunction might contribute to the degeneration.</p></sec><sec id="s2-4"><title>Dehydronitrosonisodipine (dHNN) is an inhibitor of SARM1 activation</title><p>Another prompt application of PC6 is library screening for inhibitors of SARM1. The feasibility was verified by measuring the IC<sub>50</sub> of a reported inhibitor of SARM1, nicotinamide (Nam) (<xref ref-type="bibr" rid="bib6">Essuman et al., 2017</xref>). The measured IC<sub>50</sub> value of Nam was around 140 μM, which is consistent with the reported value (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Next, we utilized this assay to screen for SARM1 inhibitors. NMN-activated SARM1 was incubated with drugs of the library (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and its activity measured with PC6 in the presence of NAD (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Out of 2015 drugs, 34 had more than 80% inhibition (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), which were further tested for inhibition of the SARM1-NADase activity using HPLC. <xref ref-type="fig" rid="fig4">Figure 4C</xref> shows the plot the IC<sub>50</sub>-values of these drugs measured with both the PC6 and the NADase/HPLC assays. Twenty-four drugs are in the middle sector, indicating they inhibited both reactions similarly. Two inhibited the PC6 activity five fold less than the NADase (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, left sector), and eight in the right sector (seven have IC<sub>50</sub>s higher than 40 μM) inhibited NADase less than the base-exchange. These remarkable differences underscore the importance of using more than one assay for drug screening (see Discussion).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Identification of dHNN as an inhibitor of SARM1.</title><p>(<bold>A</bold>) Flowchart of the PC6-based high-throughput screening. (<bold>B</bold>) Inhibitory effects of the 2015 compounds (50 μM) from an approval drug library. The activity of drug-treated SARM1-dN was determined with PC6 assay. The detail procedure and statistical analysis are referred to the 'Materials and methods' section. (<bold>C</bold>) Plot of IC<sub>50</sub>s of the 27 most potent inhibitory compounds from high-throughput screening, determined by PC6 (x axis) versus by HPLC (y axis, NADase activity) assays. See 'Materials and methods' section. (<bold>D</bold>) Inhibition curves of NSDP before (black) and after (NSDP[UV], red) UV at 254 nm for 30 min. (<bold>E</bold>) HPLC elution profile of dHNN. NSDP after 30 min UV treatment was analyzed using a C-18 column with a gradient of 0.1% TFA and ACN in 0.1% TFA. Fractions were assayed for inhibition of SARM1-dN by PC6 assay. The derivative in the elution peak was identified by MS. Black line: absorbance at 275 nm; red dots: inhibition activity. Insets: MS of the peak fraction showing its mass was the same as dHNN and the chemical structure of dHNN. (<bold>F</bold>) Concentration-inhibition curves of dHN (black solid line), UV-treated dHN (black dotted line), dHNN (red solid line) and UV-treated dHNN (red dotted line), measured by PC6 assay. PC = pyridine conjugate, NSDP = nisoldipine .</p><p> <supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig4">Figure 4B-F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig4-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Inhibitory mechanism of dHNN against SARM1.</title><p>(<bold>A</bold>) The inhibition curves of nicotinamide to SARM1-dN measured with PC6-based reaction. (<bold>B</bold>) HPLC analysis of NSDP after treating by UV at 275 nm for 20 min. Black: standard of NSDP; purple: NSDP after UV; red: standard of dHN; green: standard of dHNN. (<bold>C</bold>) The irreversibility of the inhibition of dHNN. SARM1-dN was pre-incubated with 20 μM dHNN or 5 mM Nam at rt for 20 min and washed using Centricon filter. Activity was analyzed afterward with PC6 assay. (<bold>D</bold>) Time-dependent inhibition of SARM1-dN by dHNN. SARM1-dN was incubated with 10 μM dHNN or 300 μM Nam for the indicated time and the activity was analyzed with PC6 assay. (<sc><bold>E</bold></sc>) Western blots of the cysteine-to-alanine mutants of SARM1. C215A and C226A show much lower protein expression, indicating the mutations seem to affect the stability, although the IC<sub>50</sub>s decreased to 30 μM and 11 μM, respectively, comparing to that of wildtype SARM1 (6 μM). Nam = nicotinamide, PC = pyridine conjugate, NSDP = nisoldipine.</p><p> <supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig4-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig4-figsupp1-v2.tif"/></fig></fig-group><p>In the middle sector is nisoldipine (NSDP), a calcium channel blocker having beneficial effects on neurodegenerative diseases. Peculiarly, its inhibition of SARM1 varied widely among batches. Investigations indicated the active compound was not NSDP but its derivative. <xref ref-type="fig" rid="fig4">Figure 4D</xref> shows fresh NSDP had an IC<sub>50</sub>-value of about 150 μM (squares), but its potency increased 75-fold after exposure to UV (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, triangles, IC<sub>50</sub> = 2.36 ± 0.3 μM). Also, fresh NSDP had an HPLC-elution peak at 12.2 min (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), but was completely converted by UV to a compound having a peak at 9.8 min that strongly inhibited SARM1 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, red). HRMS showed that the active compound had a mass of 370.15205 Da (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, inset) identical to a known derivative of NSDP, dehydronitrosonisoldipine (dHNN) (<xref ref-type="bibr" rid="bib27">Marinkovic et al., 2003</xref>). The HPLC-elution profile of the active compound was also the same as dHNN (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>, purple line and green dash). Indeed, authentic dHNN was active and could not be further activated by UV (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, red line and dash), which also indicates that it is photostable. Another derivative of NSDP, dehydronisoldipine (dHN, elution peak at 8.7 min, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), showed no inhibition before or after UV (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, black line and dash), indicating that the nitroso group is essential for the effect.</p></sec><sec id="s2-5"><title>dHNN inhibits SARM1 and AxD by covalently modifying cysteines</title><p>The dHNN-induced inhibition of SARM1 was irreversible by washing (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>, red bars), while that by Nam was reversible. Also, dHNN-inhibition was time-dependent, but not Nam (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>), strongly suggesting dHNN covalently reacted with SARM1.</p><p>To determine the mechanism of action of dHNN, we truncated the inhibitory ARM-domain, producing a constitutively active SAM-TIR, which showed a right-shifted inhibition curve compared to SARM1-dN (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), with around 50-fold increase in the IC<sub>50</sub>. The IC<sub>50</sub> of dHNN in the SARM1-dN-expression cells is around 4 μM, close to the IC<sub>50 </sub>in vitro. dHNN decreased the cellular cADPR in cells expressing SARM1, but not in those expressing SAM-TIR (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These results suggest that dHNN is cell-permeant and acts mainly by blocking SARM1 activation but not its enzymatic activities.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>dHNN reduces AxD by inhibiting SARM1 through covalent modification of the cysteines.</title><p>(<bold>A</bold>) Inhibition of SARM1-dN and SAM-TIR by dHNN in vitro. See 'Materials and methods'. (<bold>B</bold>) Inhibition of SARM1-dN and SAM-TIR by dHNN in cellulo. See 'Materials and methods'. (<bold>C</bold>) MS of SARM1-dN modification by dHNN. Peptide spectrum match shows that Cys311 was modified by dHNN, increasing its mass to 386.14779 Da. (<bold>D</bold>) Each cysteine in SARM1-dN was mutated to alanine. The dHNN-IC<sub>50</sub>s were measured by PC6 assay. (<bold>E</bold>) Top (left) and side (right) view of the SARM1 octamer. α-helices are shown as cylinders. dHNN modifications are shown as sticks. One protomer is colored in blue for ARM, gold for SAM, and green for TIR. The other protomers are colored in grey. (<bold>F</bold>) Zoom-in view of the dHNN-modified pocket. dHNN: purple stick; the electron density corresponding to dHNN: grey mesh; interacting residues: green; loop: red. (<bold>G</bold>) Superposition of SARM1-dHNN onto SARM1-NAD (PDB: 7mc6). SARM1-dHNN and SARM1-NAD were shown as blue and grey cartoon, respectively. The insertion loop in SARM1-dHNN was shown in red. NAD was shown as stick models and colored with gold carbons. Residues interacting with NAD, W103, R110 and R157, were shown as stick models with grey carbons. dHNN and residues interacting with dHNN were shown as in (<bold>F</bold>). (<bold>H</bold>) DRG neurons were treated with dHNN for 16 hr in the presence of VCR. The cellular cADPR contents were measured. (<bold>I</bold>) Micrographs of AxD of DRG neurons after treatment of VCR in presence of dHNN for 72 hr. (<bold>J</bold>) Quantification of AxD indices after 0, 24, 48, 72 hr treatment with VCR as in (<bold>I</bold>). AxD = axon degeneration. VCR = Vincristine.</p><p> <supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data in excel for <xref ref-type="fig" rid="fig5">Figure 5A, B, D, H and J</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig5-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>dHNN modifications on the peptides of SARM1 or nonspecific proteins analyzed by LC-MS/MS.</title><p>(<bold>A-B</bold>) Quantification of the intensity of the dHNN-modified peptides covering the indicated cysteine residues of SARM1 by LC-MS/MS following the treatment by 5 μM (<bold>A</bold>) and 50 μM (<bold>B</bold>) dHNN, and normalized with the intensity of the corresponding peptides. (<bold>C</bold>) The abundance ratio of dHNN-modified peptides to the total cysteine-containing peptides identified in SARM1 and other proteins by LC-MS/MS.</p><p> <supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data in excel of <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Data processing procedure for the SARM1-dHNN structure.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Structure of SARM1 was stabled in inactive form after dHNN treatment.</title><p>(<bold>A-B</bold>) Representative 2D class averages of SARM1-dN in the absence (<bold>A</bold>) or presence (<bold>B</bold>) of 50 μM dHNN in 100 mM Tris, 150 mM NaCl, and 1 mM EDTA at pH 8.0. (<bold>C</bold>) Local resolution estimation calculated by RELION for the 3D reconstruction of SARM1-dHNN. Left, top view; middle, bottom view; right, side view. (<bold>D</bold>) Density fit to the 3D reconstruction. (<bold>E</bold>) Superimposition of SARM1-dHNN onto SARM1-NAD (PBD codes 7cm6 and 7cm7) shows no obvious structural deviation. Left: octamer, blue for SARM1-dHNN, green for 7cm6, and grey for 7cm7; right, stereo view for the superimposition of one protomer in SARM1-dHNN and SARM-NAD (7cm6).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>dHNN attenuated the axotomy-induced AxD.</title><p>DRG neurons were pre-treated with 3 μM dHNN for 0.5 hr and axotomy performed to induce AxD. Images were captured at 0, 24, 48 hr (<bold>A</bold>) and the AxD index was analyzed by ImageJ (<bold>B</bold>). AxD = axon degeneration.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-fig5-figsupp4-v2.tif"/></fig></fig-group><p>The nitroso group of dHNN may covalently modify cysteine residues (<xref ref-type="bibr" rid="bib3">Callan et al., 2009</xref>) in SARM1. Indeed, LC-MS/MS identified several dHNN-modified peptides, among which Cys311 in the ARM domain is the dominant one (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–B</xref>). Many peptides of other proteins with cysteines were also identified but none showed modification by dHNN (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), indicating specificity of dHNN. Single mutation of all the cysteines to alanine showed that C311A significantly decreased the response to dHNN (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, the IC<sub>50</sub> of C311A was only two fold higher than that of the wildtype, which indicates dHNN might modify other cysteines when Cys311 is mutated and inactivate SARM1.</p><p>With Cryo-EM, we found that dHNN stabilized a similar inhibitory conformation of SARM1 as that induced by NAD (PDB: 7cm6) (<xref ref-type="bibr" rid="bib18">Jiang et al., 2020</xref>). In 2D-classification of the untreated SARM1, most particles presented only the SAM octamer ring (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>). For the dHNN-treated SARM1, larger octamer ring corresponding to both the SAM and ARM/TIR domains could be clearly observed (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>). Its 3D-structure was constructed at 2.4 Å resolution (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3C</xref>) with residues from 56 to 549 (ARM and SAM domains) and 561 to 702 (TIR domain) all fitted into the cryo-EM map (<xref ref-type="fig" rid="fig5">Figure 5E</xref> and <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3D</xref>). Structural superimposition with the NAD-bound SARM1 (PDB: 7cm6) (<xref ref-type="bibr" rid="bib18">Jiang et al., 2020</xref>) showed RMSD values of 0.91 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3E</xref>), suggesting that dHNN constrains SARM1 in an inactive conformation similar to that induced by NAD. Extra electron density was only observed near residue Cys311, the dHNN-target (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>), but not other cysteine residues, consistent with it being derived from dHNN (5<italic>F</italic>, purple). dHNN interacts with Glu264, Leu268, Arg307, Phe308, and Ala315 (<xref ref-type="fig" rid="fig5">Figure 5F</xref> and <xref ref-type="fig" rid="fig5">Figure 5G</xref>, green) in the ARM domain, pushing the insertion loop (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, red) toward ARM1 and stabilizes the domain. This is similar to that observed with NAD, which binds at the other side of the insertion loop and stabilizes the ARM domain possibly via ligating ARM1 and the insertion loop (<xref ref-type="fig" rid="fig5">Figure 5G</xref>).</p><p>By preventing SARM1 from activation, dHNN also inhibited the VCR-activated cADPR production (<xref ref-type="fig" rid="fig5">Figure 5H</xref>) in neurons and blocked not only the VCR-induced AxD (<xref ref-type="fig" rid="fig5">Figure 5I</xref>, third picture; <xref ref-type="fig" rid="fig5">Figure 5J</xref>, red line), as effective as knocking out SARM1 (<xref ref-type="fig" rid="fig5">Figure 5I</xref>, fourth picture), but also AxD after axotomy (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4A</xref>, third column; <italic>B</italic>, red line).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Visualizing the activity of a signaling enzyme in live cells provides clearer understanding of the spatial and temporal aspects of its mechanism and function, a goal sought by many. The PC probes developed here are particularly advantageous. They are cell-permeant, but the SARM1-catalyzed exchange products are not and accumulate in the cytosol, enhancing their detection. The remarkably large red shift of the product fluorescence provides easy visualization away from the interference of autofluorescence.</p><p>Currently, there are several fluorescent probes for SARM1 activity in use. They are all analogs of NAD and are cell-impermeant, such as εNAD. The fact that NAD is now shown to be an inhibitor of SARM1 (<xref ref-type="bibr" rid="bib18">Jiang et al., 2020</xref>; <xref ref-type="bibr" rid="bib36">Sporny et al., 2020</xref>) makes the use of these analog probes problematic, as they may affect SARM1 activity as well. PC6 has no such drawback as it is a pyridine, not an NAD analog. Furthermore, the use of PC6 requires neither expression of construct nor cell manipulation, making it suitable for detecting SARM1 activity in any cells. This is documented in this study. Using CZ-48, a cell-permeant activator, to activate endogenous SARM1 produces large increase in PAD6 fluorescence in a variety cell lines as well as primary neurons. With the probes, we provided the first direct evidence in live DRG neurons that SARM1 activation precedes AxD by several hours and that it is a necessary but insufficient factor for AxD.</p><p>Screening library to identify compounds of interest is a straightforward strategy widely used. The case for SARM1 is more complicated, as it is not only a multi-domain protein but also an auto-regulated enzyme catalyzing multiple reactions. Compounds may target the regulatory ARM domain as shown here for dHNN, or the catalytic TIR domain as Nam and the inhibitors reported during the preparation of this manuscript (<xref ref-type="bibr" rid="bib17">Hughes et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Loring et al., 2020</xref>). For SARM1, the substrates are different for the base-exchange and the NADase reactions and may thus be differentially affected by the inhibitor-induced conformational changes of the catalytic site. Although the exact reason remains to be determined, the compounds shown here that can selectively block one reaction much more than the other are of interest. Many believe that the NADase activity of SARM1, leading to cellular NAD depletion, is its dominant property for regulating AxD. But the two calcium messengers, cADPR and NAADP produced by its cyclizing and base-exchange reactions may well have functional roles as well. Compounds with differential inhibition can thus be an important tool to resolve the issue.</p><p>Much effort is being invested in targeting SARM1-mediated NAD depletion for therapeutic protection from AxD. Chemical blockers may well be an ideal tool for turning off the NAD depletion. dHNN uncovered in this study is the first compound ever described that can block the activation of SARM1, revealing a druggable allosteric site and can thus usher in a new approach for therapeutic drug development. Another point of interest is that dHNN is a derivative of NSDP. Metabolic conversion of NSDP to dHNN, leading to inhibition of SARM1, may well account for the neural protective effects of NSDP (<xref ref-type="bibr" rid="bib35">Siddiqi et al., 2019</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animals</title><p>This study was carried out in strict accordance with animal use protocol approved by Peking University Shenzhen Graduate School Animal Care and Use Committee (#AP0015001). All animals (C57BL6/J), purchased from Guangdong Medical Laboratory Animal Center (China), were handled in accordance with the guidelines of the Committee on the Ethic of Animal Experiments. All surgery was performed after euthanasia and efforts were made to minimize suffering.</p></sec><sec id="s4-2"><title>Cell lines</title><p>The HEK293 and HEK293T cells were purchased from the American Type Culture Collection and the identity has been authenticated by STR profiling. They have not been contaminated by mycoplasma. The cells were cultured in DMEM supplemented with 10% fetal calf serum and 1% penicillin-streptomycin solution and maintained in a standard humidified tissue culture incubator with 5% CO<sub>2</sub>.</p></sec><sec id="s4-3"><title>Reagents</title><p>NAD, NMN, Digitonin, Poly-L-lysine, 5-fluoro-2’-deoxyuridine and uridine, KH<sub>2</sub>PO<sub>4</sub>, NH<sub>4</sub>HCO<sub>3</sub>, and iodoacetic acid were purchased from Sigma-Aldrich. DMEM, Neurobasal Plus Medium, Trypsin-EDTA, penicillin/streptomycin solution, B27 plus, GlutaMax, Laminin, Lipofectamine 2000, ConA-Alex-647, formic acid, acetonitrile were purchased from ThermoFisher. NGF was from Sino Biological. FBS was obtained from PAN Bitotech. Approval drug library (L1000) and Nisoldipine power (Cas # 63675-72-9) were purchased from TargetMol. Dehydro Nisoldipine (Cas #103026-83-1) was obtained from TRC, while dehydronitrosonisoldipine (Cas #87375-91-5) was purchased from Glpbio and TRC. Vincristine was purchased from Selleck. General chemicals for probe synthesis were purchased from Dieckmann, Alfa, Energy, or Sangon Biotech (Shanghai).</p></sec><sec id="s4-4"><title>Synthesis and characterization of pyridine conjugates (PCs)</title><p>All air and water-sensitive reactions were carried out with anhydrous solvents in flame-dried flasks under argon atmosphere, unless otherwise specified. All the reagents were obtained commercially and used without further purification, unless otherwise specified. Anhydrous DMF was vacuum distilled from barium oxide, acetonitrile, and dichloromethane was distilled from calcium hydride. Yields refer to isolated yields, unless otherwise specified. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm silica gel plates (60 F-254) that were analyzed by UV light as visualizing method and by staining with anisaldehyde (450 mL of 95% EtOH, 25 mL of conc. H<sub>2</sub>SO<sub>4</sub>, 15 mL of acetic acid, and 25 mL of anisaldehyde) or KMnO<sub>4</sub> (200 mL H<sub>2</sub>O of 1.5 g KMnO<sub>4</sub>, 10 g K<sub>2</sub>CO<sub>3</sub> and 1.25 mL of 10% aq. NaOH). Silica gel (200–300 mesh) was used for flash column chromatography. Nuclear magnetic resonance (NMR) spectra were recorded on either a 300 (<sup>1</sup>H: 300 MHz, <sup>13</sup>C: 75 MHz), 400 (<sup>1</sup>H: 400 MHz, <sup>13</sup>C: 100 MHz), or 500 (<sup>1</sup>H: 500 MHz, <sup>13</sup>C: 125 MHz) NMR spectrometer. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet, br = broad. High resolution mass spectra (HRMS) were obtained from a MALDI-TOF mass spectrometer.</p><p>To synthesize PC1, to a stirred solution of 4-vinylpyridine (210 mg, 2.0 mmol), 4-iodoaniline (220 mg, 1.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (61 mg, 20 mol%), and triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (23 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 5 hr. The mixture was then diluted with water (20 mL) and aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave a pale-yellow solid (66 mg, 34%) as the product. PC1: mp = 272–273°C. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) δ 8.47 (d, <italic>J</italic> = 5.3 Hz, 2H), 7.46 (d, <italic>J</italic> = 6.0 Hz, 2H), 7.42–7.31 (m, 3H), 6.88 (d, <italic>J</italic> = 16.4 Hz, 1H), 6.59 (d, <italic>J</italic> = 8.5 Hz, 2H), 5.51 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<italic>d</italic><sub>6</sub>) δ 149.8, 145.4, 133.7, 128.5, 123.6, 120.0, 120.0, 113.8. HRMS (+ESI) m/z calcd. for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub> (M + H)<sup>+</sup> 197.1073, found 197.1072.</p><p>To synthesize PC2, to a stirred solution of 4-iodoaniline (0.60 g, 2.7 mmol) in DMF (7.5 mL) was added ethyl bromide (0.25 mL, 3.35 mmol) and Na<sub>2</sub>CO<sub>3</sub> (0.50 g, 4.72 mmol) at rt. The resulting mixture was stirred at 70°C for 6 hr. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were washed with water (15 mL ×3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 1:20) gave a brown solid (79 mg, 12%) as the product (<bold>1</bold>). Spectral data of <bold>1</bold> are consistent with those reported in the literature.(<xref ref-type="bibr" rid="bib30">Ni et al., 2017</xref>) To a stirred solution of 4-vinlypridine (53 mg, 0.5 mmol), <bold>1</bold> (74 mg, 0.3 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (30 mg, 20 mol%), and triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (5 mL) under argon was added Pd(OAc)<sub>2</sub> (11 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 12 hr. The mixture was then diluted with water (20 mL) and aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 2:1) of the residue gave a pale-orange solid (51 mg, 76%) as the product. PC2: mp = 199–200°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.52 (d, <italic>J</italic> = 5.8 Hz, 2H), 7.39 (d, <italic>J</italic> = 8.5 Hz, 2H), 7.31 (dd, <italic>J</italic> = 4.7, 1.4 Hz, 2H), 7.23 (d, <italic>J</italic> = 16.3 Hz, 1H), 6.79 (d, <italic>J</italic> = 16.2 Hz, 1H), 6.60 (d, <italic>J</italic> = 8.6 Hz, 2H), 3.21 (q, <italic>J</italic> = 7.1 Hz, 2H), 1.29 (t, <italic>J</italic> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 149.9, 149.0, 145.5, 133.4, 128.5, 125.2, 121.2, 120.4, 112.6, 38.2, 14.8. HRMS (+ESI) m/z calcd. for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub> (M + H)<sup>+</sup> 224.1386, found 224.1382.</p><p>To synthesize PC3, to a stirred solution of 4-iodoaniline (1.2 g, 5.5 mmol) in DMF (15 mL) was added ethyl bromide (2.0 mL, 27 mmol) and Na<sub>2</sub>CO<sub>3</sub> (1.0 g, 9.4 mmol) at rt. The resulting mixture was stirred at 70°C for 6 hr. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were washed with water (15 mL ×3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. Silica gel flash column chromatography of the residue (ethyl acetate/hexanes = 1: 30) gave a brown oil (814 mg, 54%) as the product (<bold>2</bold>). Spectral data of <bold>2</bold> is consistent with those reported.(<xref ref-type="bibr" rid="bib19">Kolvari et al., 2014</xref>) To a stirred solution of <bold>2</bold> (273 mg, 1.0 mmol), 4-vinylpyridine (210 mg, 2.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (61 mg, 20 mol%), and triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (23 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 12 hr. The mixture then was diluted with water (20 mL) and the aqueous phase extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 1:1) of the residue gave a pale-yellow solid (138 mg, 55%) as the product. <bold>PC3</bold>: mp = 184–185°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50 (d, <italic>J</italic> = 5.6 Hz, 2H), 7.47–7.38 (m, 2H), 7.30 (d, <italic>J</italic> = 6.1 Hz, 2H), 7.25–7.19 (m, 1H), 6.74 (t, <italic>J</italic> = 16.9 Hz, 1H), 6.66 (t, <italic>J</italic> = 5.9 Hz, 2H), 3.47–3.18 (m, 4H), 1.31–1.02 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 149.9, 148.2, 145.7, 133.4, 128.6, 123.2, 120.4, 120.4, 111.5, 44.5, 12.7. HRMS (+ESI) m/z calcd. for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub> (M + H)<sup>+</sup> 253.1699, found 253.1699.</p><p>To synthesize PC4, to a stirred solution of <bold>2</bold> (273 mg, 1.0 mmol), 1-bromo-4-vinylbenzene (183 mg, 1.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (61 mg, 20 mol%), triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (23 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°<sup>C</sup> for 12 hr. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. Silica flash column chromatography (ethyl acetate/hexanes = 1:30) gave a pale green solid (234 mg, 71%) as the product (<bold>3</bold>). Spectral data of <bold>3</bold> are consistent with those reported in the literature.(<xref ref-type="bibr" rid="bib24">Lemercier et al., 2006</xref>) To a stirred solution of <bold>3</bold> (165 mg, 0.50 mmol), 4-vinlypyridine (105 mg, 1.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (30 mg, 20 mol%), and triethylamine (0.20 mL, 1.5 mmol) in degassed CH<sub>3</sub>CN (10 mL) under argon was added Pd(OAc)<sub>2</sub> (11 mg, 10%) quickly. The resulting mixture was stirred at 100°C for 12 hr. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave a pale-yellow solid (128 mg, 72%) as the product. PC4: mp = 225-226 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.54 (d, <italic>J</italic> = 5.7 Hz, 2H), 7.54–7.44 (m, 4H), 7.42–7.38 (m, 2H), 7.36 (d, <italic>J</italic> = 6.0 Hz, 2H), 7.29 (d, <italic>J</italic> = 16.3 Hz, 1H), 7.09 (d, <italic>J</italic> = 16.2 Hz, 1H), 6.99 (d, <italic>J</italic> = 16.3 Hz, 1H), 6.88 (d, <italic>J</italic> = 16.2 Hz, 1H), 6.67 (d, <italic>J</italic> = 8.9 Hz, 2H), 3.39 (q, <italic>J</italic> = 7.0 Hz, 4H), 1.19 (t, <italic>J</italic> = 7.0 Hz, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 150.1, 147.6, 144.9, 139.1, 134.2, 133.1, 129.7, 129.0, 128.6, 128.0, 127.4, 126.3, 124.9, 124.4, 122.9, 120.8, 111.7, 44.4, 12.7. HRMS (+ESI) m/z calcd. for C<sub>25</sub>H<sub>26</sub>N<sub>2</sub> (M + H)<sup>+</sup> 355.2169, found 355.2167.</p><p>To synthesize PC5, to a stirred solution of 4-vinylpyridine (210 mg, 2.0 mmol), 4-iodophenol (220 mg, 1.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (61 mg, 20 mol%), and triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (23 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 12 hr. The mixture was then diluted with water (20 mL). Upon addition of 5% HCl leads to partial precipitation of the product. The aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave an off-white solid (130 mg, 66%) as the product. <bold>PC5</bold>: mp = 281–282. <sup>1</sup>H NMR (400 MHz, DMSO-<italic>d</italic><sub>6</sub>) δ 9.83 (s, 1H), 8.55 (d, <italic>J</italic> = 4.5 Hz, 2H), 7.67–7.42 (m, 5H), 7.07 (d, <italic>J</italic> = 16.4 Hz, 1H), 6.85 (d, <italic>J</italic> = 9.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<italic>d</italic><sub>6</sub>) δ 158.2, 149.8, 144.8, 133.1, 128.7, 127.2, 122.4, 120.5, 115.7. HRMS (+ESI) m/z calcd. for C<sub>13</sub>H<sub>11</sub>NO (M + H)<sup>+</sup> 198.0913, found 198.0913.</p><p>To synthesize PC6, to a stirred solution of 4-vinylpyridine (631 mg, 6.0 mmol), 1-ethoxy-4-iodobezene (1.24 g, 5.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (305 mg, 20 mol%), and triethylamine (2.0 mL, 15 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (112 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 12 hr. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave an off-white solid (958 mg, 85%) as the product. PC6: mp = 146–147°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.55 (dd, <italic>J</italic> = 4.6, 1.5 Hz, 2H), 7.51–7.42 (m, 2H), 7.33 (dd, <italic>J</italic> = 4.6, 1.5 Hz, 2H), 7.27 (t, <italic>J</italic> = 8.1 Hz, 1H), 6.97–6.81 (m, 3H), 4.07 (q, <italic>J</italic> = 7.0 Hz, 2H), 1.44 (t, <italic>J</italic> = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 159.6, 150.1, 145.0, 132.8, 128.7, 128.4, 123.6, 120.6, 114.8, 63.6, 14.8. HRMS (+ESI) m/z calcd. for C<sub>15</sub>H<sub>15</sub>NO (M + H)<sup>+</sup> 226.1226, found 226.1226.</p><p>To synthesize PC7, to a stirred solution of 4-iodophenol (1.09 g, 4.93 mmol) and triethylamine (749 mg, 7.40 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) was added acetyl chloride (465 mg, 5.92 mmol) at rt. The resulting mixture was stirred at 0°C for 20 min and then rt for 2 hr. The solution was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under reduced pressure. The resulting pale brown oil (1.15 g, 89%) was obtained as the product (<bold>4</bold>) and was used for the next step without any further manipulation. Spectral data of <bold>4</bold> is consistent with those reported in the literature (<xref ref-type="bibr" rid="bib9">Flaherty et al., 2010</xref>). To a stirred solution of 4-vinylpyridine (210 mg, 2.0 mmol), 4 (240 mg, 1.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (61 mg, 20 mol%), and triethylamine (0.40 mL, 2.9 mmol) in degassed CH<sub>3</sub>CN (15 mL) under argon was added Pd(OAc)<sub>2</sub> (23 mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 6 hr. The mixture was then diluted with water (30 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave a white solid (103 mg, 43%) as the product. PC7: mp = 152–153°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58 (d, <italic>J</italic> = 5.9 Hz, 2H), 7.63–7.48 (m, 2H), 7.36 (dd, <italic>J</italic> = 4.7, 1.4 Hz, 2H), 7.28 (d, <italic>J</italic> = 16.3 Hz, 1H), 7.15–7.09 (m, 2H), 6.97 (d, <italic>J</italic> = 16.3 Hz, 1H), 2.32 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 150.9, 150.2, 144.5, 133.9, 132.2, 128.1, 126.2, 122.1, 120.9, 21.2. HRMS (+ESI) m/z calcd. for C<sub>15</sub>H<sub>13</sub>NO<sub>2</sub> (M + H)<sup>+</sup> 240.1019, found 240.1018.</p><p>To synthesize PC8, to a stirred solution of 5-bromo-2-hydroxy-benzonitrile (0.60 g, 30 mmol) in DMF (7 mL) was added ethyl bromide (0.37 mL, 5.0 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.0 g, 9.4 mmol) at rt. The resulting mixture was stirred at 70°C for 6 hr. The mixture was then diluted with water (20 mL), and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were washed with water (15 mL ×3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated under reduced pressure. A white solid was obtained as the product (<bold>12</bold>). To a stirred solution of the crude product (<bold>12</bold>), 4-vinylpyridine (315 mg, 3.0 mmol), P(<italic>o</italic>-tol)<sub>3</sub> (183 mg, 20 mol%), and triethylamine (1.2 mL, 8.7 mmol) in degassed CH<sub>3</sub>CN (30 mL) under argon was added Pd(OAc)<sub>2</sub> (67mg, 10 mol%) quickly. The resulting mixture was stirred at 100°C for 5 hr. The mixture was then diluted with water (30 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) of the residue gave a pale-yellow solid (433 mg, 58%) as the product. <bold>PC8</bold>: mp = 114–115°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59 (d, <italic>J</italic> = 5.9 Hz, 2H), 7.80–7.60 (m, 2H), 7.35 (d, <italic>J</italic> = 5.9 Hz, 2H), 7.19 (d, <italic>J</italic> = 16.3 Hz, 1H), 6.99 (d, <italic>J</italic> = 8.8 Hz, 1H), 6.91 (d, <italic>J</italic> = 16.3 Hz, 1H), 4.19 (q, <italic>J</italic> = 7.0 Hz, 2H), 1.50 (t, <italic>J</italic> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 160.4, 150.0, 143.9, 132.5, 131.8, 130.2, 128.9, 125.7, 120.6, 115.9, 112.3, 102.4, 64.8, 14.3. HRMS (+ESI) m/z calcd. for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O (M + H)<sup>+</sup> 251.1179, found 251.1178.</p><p>To synthesize PC9, to a stirred solution of 1-ethoxy-4-iodobezene (1.24 g, 5.0 mmol) and 3,3-diethoxyprop-1-ene (1.03 g, 7.9 mmol), P(<italic>o</italic>-tol) (305 mg, 20 mol%), Cs<sub>2</sub>CO<sub>3</sub> (2.28 g, 7.0 mmol) and KCl (370 mg, 5 mmol) in DMF (30 mL) under argon was added Pd(OAc)<sub>2</sub> (115 mg, 10 mol%) quickly. The resulting mixture was stirred at 90°C for 5 hr and then treated with 5% HCl (10 mL) and stirred at rt for 10 min. The mixture was then diluted with water (20 mL) and the aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 1:5) gave a pale-yellow solid (443 mg, 50%) as the product (<bold>6</bold>). Spectral data of <bold>6</bold> is consistent with those reported in the literature (<xref ref-type="bibr" rid="bib20">Lator et al., 2018</xref>). To a stirred solution of <bold>6</bold> (88 mg, 0.50 mmol), 4-methylpyridine (93 mg, 1.0 mmol) in Ac<sub>2</sub>O (2 cmL) was added NaOAc (272 mg, 2.0 mmol) at rt. The resulting mixture was heated under reflux for 21 hr. Then the mixture was cooled to rt and diluted with CH<sub>2</sub>Cl<sub>2</sub>, washed with H<sub>2</sub>O, 5% HCl, H<sub>2</sub>O, and saturated aqueous NaHCO<sub>3</sub>. The aqueous phase was extracted with ethyl acetate (15 mL ×3). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated under reduced pressure. Silica gel flash column chromatography (ethyl acetate/hexanes = 3:1) gave a pale-yellow solid (47 mg, 37%) as the product. <bold>PC9</bold>: mp = 132–133°C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58 (d, <italic>J</italic> = 5.9 Hz, 2H), 7.44 (d, <italic>J</italic> = 8.7 Hz, 2H), 7.36–7.29 (m, 2H), 7.17 (dd, <italic>J</italic> = 15.5, 10.2 Hz, 1H), 6.99–6.74 (m, 4H), 6.57 (d, <italic>J</italic> = 15.5 Hz, 1H), 4.11 (d, <italic>J</italic> = 7.0 Hz, 2H), 1.48 (t, <italic>J</italic> = 7.0 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.0, 149.8, 144.7, 135.4, 133.8, 129.2, 128.2, 127.9, 125.8, 120.3, 114.6, 63.3, 14.6.HRMS (+ESI) m/z calcd. for C<sub>17</sub>H<sub>18</sub>NO (M + H)<sup>+</sup> 252.1383, found 252.1384.</p></sec><sec id="s4-5"><title>Preparation and quantification of the enzymes</title><p>A truncated form of SARM1, SARM1-dN, was prepared as described (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). In brief, the recombinant protein, SARM1 without the N-terminal mitochondrial signal, was expressed in HEK293T cells and released by 100 μM digitonin in PBS with protease inhibitor cocktail (Roche). The cell lysate of wildtype HEK293T, prepared with the same method, was used as the negative control. To quantify SARM1-dN, the protein was pulled down by BC2 nanobody (<xref ref-type="bibr" rid="bib2">Bruce and McNaughton, 2017</xref>) conjugated beads which were prepared by conjugating BC2 nanobody to NHS-beads (GE Healthcare). The purified SARM1-dN, named as SARM1-IP, together with the certain amounts of standard protein BSA, was applied to SDS-PAGE, which was stained by Coomassie blue. The protein contents of SARM1-dN were then calculated by the band intensity with BSA as standards.</p><p>DtSARM1-dN, with the N-terminal targeting signal removed and tagged with a tandem strep tag II and flag tag for purification, was constructed into Plenti-CMV-puro-Dest (Invitrogene) by LR clonase II enzyme according to the manufacturer’s instructions. HEK293F cells overexpressing dtSARM1-dN were constructed by lentivirus infection and selected with 1 μg/mL puromycin. DtSARM1-dN was released by 200 μM digitonin and immunoprecipitated with StrepTactin resin (GE healthcare), washed with buffer W (100 mM Tris-HCl pH8.0, 150 mM NaCl and 1 mM EDTA) for four times and eluted with 2 mM biotin in buffer W. DtSARM1-dN was used in the experiments on the dHNN-modification, cysteine-to-alanine mutants and Cryo-EM structures.</p><p>Recombinant CD38 and <italic>N. crassa</italic> NADase were prepared as described previously (<xref ref-type="bibr" rid="bib13">Graeff et al., 1994</xref>; <xref ref-type="bibr" rid="bib29">Munshi et al., 1997</xref>).</p></sec><sec id="s4-6"><title>In vitro fluorescence assays</title><p>To analyze the activity of SARM1 with PCs in vitro, reactions were started by incubating the enzyme with the reaction mixture, 50 μM PC, 100 μM NAD, and 100 μM NMN in PBS. The absorbance and fluorescence were measured in a quartz cuvette or black 96-well plates (Corning), respectively, in an Infinite M200 PRO microplate reader (Tecan). For the assays with εNAD，NHD, or NGD as the substrate, 100 μM of each probe was incubated with the enzymes and the kinetics of fluorescence production was measured at λ<sub>ex</sub> = 300 nm, λ<sub>em</sub> = 410 nm. The initial rate of the reactions was quantified with the slope of the fluorescence increase in the first several minutes.</p></sec><sec id="s4-7"><title>HPLC analysis of the base-exchange reaction</title><p>The reactions were prepared by mixing SARM1-IP (SARM1 binding on BC2-beads, around 2.5 μg/mL) with 100 μM NAD, 50 μM PC6, 100 μM NMN, and 0.1 mg/mL BSA in PBS and incubated for 60 min at 37°C. SARM1-IP was removed by centrifugation at 4,500 rpm for 1 min. The cleaned mixtures were applied to a C-18 reverse phase column equipped on an HPLC (Agilent 1260) with a gradient of 0.1 M KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) and 0.1 M KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) with MeOH (7:3) to elute NMN, cAPPR, ADPR, NAD, and a gradient of ACN from 30 to 70% to elute PAD6 and PC6. The PAD6 fractions were collected and lyophilized for the characterization of absorption and fluorescence spectra.</p><p>To analyze PAD6 in cells, the metabolites were extracted from the cells treated with 50 μM PC6 by 0.6 M perchloric acid, followed by the neutralization with Chloroform: Tri-n-octylamine (3:1). The extracts were applied to a C-18 column and PAD6 was eluted with water and acetonitrile by 2% acetonitrile for 8 min, then 30% acetonitrile for 8 min.</p></sec><sec id="s4-8"><title>Confocal imaging of PAD6 in living cells</title><p>HEK293 cells, overexpressing wildtype or the enzymatically dead form (E642A) of SARM1 or HEK293T Knocking out <italic>NMNAT1</italic> were constructed as before (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). Cells, grown on 0.05 mg/mL poly-L-lysine coated Chambered coverglass (ThermoFisher, #155411) overnight, were treated with 50 μM PC6 in the presence or absence of 100 μM CZ-48 for 8 hr (for SARM1-OE cells) and 200 μM CZ-48 for 48 hr (for wildtype HEK293T cells), respectively. To demonstrate the edges of the cells, they were stained with 50 μg/mL Concanavalin A, Alexa Fluor 647 Conjugate (ThermoFisher) at 4°C for 10 min before imaging. The fluorescence signals (Ex/Em: 405/525 nm for PAD6; Ex/Em: 561/590 for ConA) were captured under a confocal microscope (Nikon A1).</p></sec><sec id="s4-9"><title>Analysis of PAD6 signals in live cells by flow cytometry</title><p>HEK293 cell line carrying doxycycline (Dox)-inducible SARM1 was constructed as previously described (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). The cells were treated with 50 μM PC6, 100 μM CZ-48, or 0.5 mg/mL Dox for 4, 8, 12, and 16 hr. The cells were trypsinized and the fluorescence of PAD6 (Ex/Em: 405/525 nm) was analyzed by flow cytometry (CytoFlex, Beckman).</p></sec><sec id="s4-10"><title>DRG culture and imaging</title><p>Mouse DRG culture was performed as described (<xref ref-type="bibr" rid="bib34">Sasaki et al., 2016</xref>). Briefly, DRGs were dissected from the embryos at day 12.5 to 14.5 (E12.5-E14.5), dispersed by 0.05% Trypsin solution containing 0.02% EDTA (Gibco), and seeded in Neurobasal Plus Medium supplemented with 2% B27 plus, 1 mM GlutaMax, 1% penicillin/streptavidin solution, and 37.5 ng/mL NGF on the Chambered coverglass pre-coated with (0.1 mg/mL) poly-L-Lysine, (0.02 mg/mL) laminin, and 5% FBS. Every 3 days, 50% of the culture media was replaced by fresh media with the addition of 5 μM 5-fluoro-2’-deoxyuridine and 5 μM uridine.</p><p>On div6, the neurons were infected with lentivirus carrying various expression cassettes of genes or shRNAs. Three days later, the cells were treated with 50 μM PC6 in the absence or presence of 200 μM CZ-48 or 50 nM vincristine. The fluorescence images (Ex/Em: 405/520 nm for PAD6; Ex/Em: 561/590 for TdTomato) were captured under a confocal microscope (Nikon A1) with a 60x object. The mean fluorescence intensity was quantified by NIS-Elements AR analysis (Nikon). Axon degeneration was quantified based on axon morphology using ImageJ. The TdTomato fluorescence images were binarized and measured the total axon area (size = 20 infinity pixels) and the degenerated axon (size = 20–4,000,000 pixels) with particle analyzer module of ImageJ. Axon degeneration index was calculated as the ratio of the degeneration axon over total axon area.</p><p>Lentivirus preparation and infection of DRG neurons pLKO.1-shRNA-<italic>Sarm1</italic> plasmids were constructed as described previously (<xref ref-type="bibr" rid="bib39">Zhao et al., 2019</xref>). Briefly, the shRNA targeting mouse <italic>Sarm1</italic> (5’- <named-content content-type="sequence">CCGGCTGGTTTCTTACTCTACGAATCTCGAGATTCGTAGAGTAAGAAACCAGTTTTTG</named-content>-3’) or the scrambled shRNA (5’- <named-content content-type="sequence">CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTG</named-content>-3’) were inserted to pLKO.1-puro (Addgene, #8453) with EcoRI and AgeI, followed by the replacement of the puromycin resistance gene with a fluorescent protein, TdTomato (GenBank: LC311026.1) with KpnI/BamHI. The lentiviral particles were prepared by transfecting HEK293T cells with the corresponding lentivectors, pMD2.G, and psPAX2 (<xref ref-type="bibr" rid="bib25">Liu et al., 2017</xref>) and concentrated with Lenti-Concentin Virus Precipitation Solution (ExCell Bio). The viral particles were finally resuspended in Neurobasal Plus Medium. The virus titer was determined by series infection of HEK293T cells. The virus was added to infect the DRG neurons on div6 with the same MOIs and the experiments were carried out 72 hr after infection.</p></sec><sec id="s4-11"><title>Imaging and quantification of AxD after axotomy and vincristine treatment</title><p>For axotomy, one DRG was seeded into a 24-well plate, and 5 μM 5-fluoro-2’-deoxyuridine and 5 μM uridine were added on the other day. On div5, axons were pre-incubated with the drugs for 0.5 hr and severed near the soma with a 3 mm flat blade under microscope guidance to remove the cell bodies. For vincristine treatment, DRGs were digested with 0.05% Trypsin and seeded into 24-well plates. DRGs on div9-13 were incubated with 50 nM vincristine in the presence or absence of the candidate drugs.</p><p>About 9–12 images of the axon were acquired in the bright field with a 20x object for each treatment at the indicated time points using invert optical microscope (Olympus). Axon degeneration was quantified using ImageJ. For each treatment, 60 random grid-squares with 147 × 147 pixels were cropped, binarized and the total axon area (size = 16 infinity pixels) and the degenerated axon (size = 16–10,000 pixels) were quantified with the particle analyzer module of ImageJ. Axon degeneration index was calculated as the ratio of the degeneration axon over total axon area.</p></sec><sec id="s4-12"><title>Measurement of the cADPR levels in DRGs</title><p>DRG neurons were treated with 50 nM Vincristine or 200 μM CZ-48 for 0, 12, 24, 48 hr on div6. After incubation, DRG was washed with cold PBS and lysed with 0.6 M perchloric acid. The concentration of cADPR was analyzed by the cycling assay, as described previously (<xref ref-type="bibr" rid="bib15">Graeff and Lee, 2002</xref>).</p></sec><sec id="s4-13"><title>Q-RT-PCR</title><p>The total RNAs were extracted from DRG neurons with RNA extraction kit (OMEGA) 48 hr post infection and transcribed with the kit, Transcript II One-step gDNA Removal and cDNA synthesis Supermix from Sangon Biotech. The mRNA level of SARM1 relative to GAPDH was quantified with by Q-RT-PCR using TransStart Tip Green qPCR SuperMix (TransGen Biotech) on CFX Connect Real-Time PCR Detection System (Bio-Rad). The following primer pairs were used: <italic>Sarm1</italic> sense, 5’-<named-content content-type="sequence">CTTTCTCCAAGGAGGACGAGC</named-content>-3’, antisense, 5’-<named-content content-type="sequence">CTTGTGTCACTGGCATCCACC</named-content>-3’; GAPDH sense, 5’- <named-content content-type="sequence">TGGCCTTCCGTGTTCCTAC</named-content>-3’, antisense, 5’-<named-content content-type="sequence">GAGTTGCTGTTGAAGTCGCA</named-content>-3’.</p></sec><sec id="s4-14"><title>PC6 assay</title><p>For high-throughput screening of the potential inhibitors, 1.5 μg/mL SARM1-dN was pre-incubated with 50 μM drugs (TargetMol, L1000) at room temperature for 10 min and the reaction reagents, including 20 μM PC6, 50 μM NAD, and 50 μM NMN were added to start the reaction. Controls including reactions without the drugs, defined as 0% inhibition, and without both the drugs and SARM1-dN, defined as 100% inhibition. The fluorescence (ex: 390 nm; em: 520 nm) was measured by plate reader (Tecan, M200Pro) and the initial reaction rates were calculated, V<sub>x</sub> for the reactions with different drugs, V<sub>max</sub> for the reaction without drugs and V<sub>min</sub> for the reaction without enzyme. The inhibitory rates were calculated by the equation, (V<sub>max</sub>- V<sub>x</sub>)/V<sub>max</sub> and plotted using GraphPad Prism 8.0. The standard statistics of the screening were calculated as follows: Z' factor=1-(3*SD(V<sub>max</sub>)+3*SD(V<sub>min</sub>))/(Average(V<sub>max</sub>)-Average(V<sub>min</sub>)), S/N = (Average(V<sub>max</sub>)-Average(V<sub>min</sub>))/SD(V<sub>min</sub>). In the screening of this study, Z’ = 0.69 and S/N = 291.96.</p><p>For IC<sub>50</sub> measurement, 0.4 μg/mL SARM1-dN was pre-incubated with doses of drugs in vitro for 10 min, and started the reaction by adding 50 μM NAD, 50 μM NMN, and 50 μM PC6. Calculation of IC<sub>50</sub> by plotting the initial rate to dose of compounds.</p></sec><sec id="s4-15"><title>NADase acitivity of SARM1 analyzed by HPLC</title><p>1 μg/mL of SARM1-dN was pre-incubated with drugs for 15 min at room temperature, and the reactions were started by adding 100 μM NAD and 100 μM NMN. They were stopped by removing the enzyme with MultiScreen Filter Plates (Millipore) after 0, 15, and 30 min incubation at 37°C and the reactants and products were analyzed by a C-18 column (Aligent, 20 RBAX SB-C18) with a gradient of 0.1 M KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) and 0.1 M KH<sub>2</sub>PO<sub>4</sub> (pH 6.0) with MeOH (7:3) to elute NMN, cAPPR, ADPR, NAD, Nam. The amount of ADPR was used to calculate the initial rate. IC<sub>50</sub> was calculated by Graphpad Prism 8.0.</p></sec><sec id="s4-16"><title>HPLC analysis of NSDP and its derivatives</title><p>The NSDP powder was dissolved in DMSO and shined with UV at 254 nm for 30 min and analyzed with a C-18 reverse phase column (ZORBAX SB-C18) equipped on a HLPC (Aligent 1260) and eluted with 50% of 0.1%TFA and 50% of 0.1%TFA in 99% ACN. The products after UV treatment were collected and purified by HPLC, as described above. The inhibitory activity of these fractions was determined by PC6 assay after being neutralized with 100 mM Tris (pH7.5), and the main peak was characterized by HRMS (Thermo, Q Exactive Focus).</p></sec><sec id="s4-17"><title>The inhibitory activity of dHNN in vitro and in cellulo</title><p>To determine whether dHNN inhibits the activation or enzymatic activity of SARM1 in vitro, SARM1-dN, the autoinhibited form, and SAM-TIR, the constitutively active form, were pre-incubated with different concentrations of dHNN at rt for 10 min, after which the activity was measured with PC6 assay and the inhibition rate was calculated.</p><p>To test the same effect in cellulo, HEK293 cells overexpressing the inducible SARM1 (iSARM1) or SAM-TIR (iSAM-TIR) were pre-incubated with 20 μM dHNN, or DMSO as controls, for 1.5 hr and then treated with 100 μM CZ-48 or 0.5 μg/mL Dox for the indicated time. The cellular levels of cADPR were measured as described above.</p></sec><sec id="s4-18"><title>Modification of SARM1 by dHNN</title><p>The dtSARM-dN, eluted from the StrepTactin beads, was incubated with 0, 5, or 50 μM dHNN at rt for 40 min and applied to SDS-PAGE. After simplyBlue SafeStain (ThermoFisher), the dtSARM1-dN band was sliced, dehydrated with 100% ACN, and the proteins were alkylated by 22.5 mM IAA for 30 min in dark after the reduction by 10 mM DTT at 55°C for 30 min. After overnight in-gel digestion with Trypsin, the peptides were extracted and analyzed with HRMS (Thermo, Q Exactive HF-X). The dHNN modifications, determined by Protein Discoverer software (ThermoFisher), were defined as an increase of molecular weight by 370.153 Da, 354.158 Da, 402.143 Da, or 386.148 Da on the cysteine residues characterized in the MS<sup>2</sup> fragments (<xref ref-type="bibr" rid="bib3">Callan et al., 2009</xref>; <xref ref-type="bibr" rid="bib28">Möller et al., 2017</xref>). The abundance of each peptide was determined in the MS<sup>1</sup>. Abundance ratio was calculated by dividing the intensity of the dHNN-modified peptides by that of the corresponding peptides.</p></sec><sec id="s4-19"><title>Cysteine mutants</title><p>The cysteine-to-alanine mutants of dtSARM1-dN were amplified by the overlapping PCRs with the primers, listed below, and subcloned into pCDH-EF1-MCS-IRES-neo by Xba I and Not I. To prepare the mutant proteins, HEK293 cells were transfected with the above plasmids by lipofectamine 2000 or Polyethylenimine according to the manufacturer’s instructions, and the proteins were extracted 48–72 hr after transfection and determined the IC<sub>50</sub> of dHNN by PC6 assay in vitro.</p><list list-type="simple"><list-item> <p>C117A-F: 5’-<named-content content-type="sequence">GTAGCCCAGGGTCTGGCC GACGCCATCCGC</named-content>-3’</p> </list-item> <list-item> <p>C117A-R: 5’-<named-content content-type="sequence">GCGGATGGCGTCGGCCAGACCCTGGGCTAC</named-content>-3’</p> </list-item> <list-item> <p>C199A-F: 5’-<named-content content-type="sequence">CATTCGGAGGAGACAGCC CAGAGGCTGGTG</named-content>-3’</p> </list-item> <list-item> <p>C199A-R: 5’-<named-content content-type="sequence">CACCAGCCTCTGGGCTGTCTCCTCCGAATG</named-content>-3’</p> </list-item> <list-item> <p>C215A-F: 5’-<named-content content-type="sequence">GCGGTGCTGTATTGGGCACGCCGCACGGAC</named-content>-3’</p> </list-item> <list-item> <p>C215A-R: 5’-<named-content content-type="sequence">GTCCGTGCGGCGTGCCCAATACAGCACCGC</named-content>-3’</p> </list-item> <list-item> <p>C226A-F: 5’-<named-content content-type="sequence">GCGCTGCTGCGCCACGCAGCGCTGGCGCTG</named-content>-3’</p> </list-item> <list-item> <p>C226A-R: 5’-<named-content content-type="sequence">CAGCGCCAGCGCTGCGTGGCGCAGCAGCGC</named-content>-3’</p> </list-item> <list-item> <p>C233A-F: 5’-<named-content content-type="sequence">CTGGCGCTGGGCAACGCAGCGCTGCACGGG</named-content>-3’</p> </list-item> <list-item> <p>C233A-R: 5’-<named-content content-type="sequence">CCCGTGCAGCGCTGCGTTGCCCAGCGCCAG</named-content>-3’</p> </list-item> <list-item> <p>C271A-F: 5’-<sc><named-content content-type="sequence">CTTCGGCTGCACGCCGCACTCGCAGTAGCG</named-content></sc>-3’</p> </list-item> <list-item> <p>C271A-R: 5’-<named-content content-type="sequence">CGCTACTGCGAGTGCGGCGTGCAGCCGAAG</named-content>-3’</p> </list-item> <list-item> <p>C311A-F: 5’-<named-content content-type="sequence">GGCCGCTTCGCCCGCGCC CTGGTGGACGCC</named-content>-3’</p> </list-item> <list-item> <p>C311A-R: 5’-<named-content content-type="sequence">GGCGTCCACCAGGGCGCGGGCGAAGCGGCC</named-content>-3’</p> </list-item> <list-item> <p>C343A-F: 5’-<named-content content-type="sequence">CGCTTGGAGGCGCAGGCAATCGGGGCTTTC</named-content>-3’</p> </list-item> <list-item> <p>C343A-R: 5’-<named-content content-type="sequence">GAAAGCCCCGATTGCCTGCGCCTCCAAGCG</named-content>-3’</p> </list-item> <list-item> <p>C350A-F: 5’-<named-content content-type="sequence">GGGGCTTTCTACCTCGCAGCCGAGGCTGCC</named-content>-3’</p> </list-item> <list-item> <p>C350A-R: 5’-<named-content content-type="sequence">GGCAGCCTCGGCTGCGAGGTAGAAAGCCCC</named-content>-3’</p> </list-item> <list-item> <p>C430A-F: 5’-<named-content content-type="sequence">GGTTTCTCCAAGTACGCAGAGAGCTTCCGG</named-content>-3’</p> </list-item> <list-item> <p>C430A-R: 5’-<named-content content-type="sequence">CCGGAAGCTCTCTGCGTACTTGGAGAAACC</named-content>-3’</p> </list-item> <list-item> <p>C482A-F: 5’-<named-content content-type="sequence">GCCAACTATTCTACGGCC GACCGCAGCAAC</named-content>-3’</p> </list-item> <list-item> <p>C482A-R: 5’-<named-content content-type="sequence">GTTGCTGCGGTCGGCCGTAGAATAGTTGGC</named-content>-3’</p> </list-item> <list-item> <p>C508A-F: 5’-<named-content content-type="sequence">TACGGCCTGGTCAGCGCAGGCCTGGACCGC</named-content>-3’</p> </list-item> <list-item> <p>C508A-R: 5’-<named-content content-type="sequence">GCGGTCCAGGCCTGCGCTGACCAGGCCGTA</named-content>-3’</p> </list-item> <list-item> <p>C527A-F: 5’-<named-content content-type="sequence">CAGCTGCTGGAAGACGCAGGCATCCACCTG</named-content>-3’</p> </list-item> <list-item> <p>C527A-R: 5’-<named-content content-type="sequence">CAGGTGGATGCCTGCGTCTTCCAGCAGCTG</named-content>-3’</p> </list-item> <list-item> <p>C552A-F: 5’-<named-content content-type="sequence">CACTCCCCGCTGCCCGCAACTGGTGGCAAAC</named-content>-3’</p> </list-item> <list-item> <p>C552A-R: 5’-<named-content content-type="sequence">GTTTGCCACCAGTTGCGGGCAGCGGGGAGTG</named-content>-3’</p> </list-item> <list-item> <p>C629A-F: 5’-<named-content content-type="sequence">GGAGCACTGGACAAGGCAATGCAAGACCAT</named-content>-3’</p> </list-item> <list-item> <p>C629A-R: 5’-<named-content content-type="sequence">ATGGTCTTGCATTGCCTTGTCCAGTGCTCC</named-content>-3’</p> </list-item> <list-item> <p>C635A-F: 5’-<named-content content-type="sequence">ATGCAAGACCATGACGCAAAGGATTGGGTG</named-content>-3’</p> </list-item> <list-item> <p>C635A-R: 5’-<named-content content-type="sequence">CACCCAATCCTTTGCGTCATGGTCTTGCAT</named-content>-3’</p> </list-item> <list-item> <p>C649A-F: 5’-<named-content content-type="sequence">GTGACTGCTTTAAGCGCC GGCAAGAACATT</named-content>-3’</p> </list-item> <list-item> <p>C649A-R: 5’-<named-content content-type="sequence">AATGTTCTTGCCGGCGCTTAAAGCAGTCAC</named-content>-3’ </p> </list-item> <list-item> <p>dtSARM1-dN-F: 5’-<named-content content-type="sequence">CAGTCTAGAATGGACTACAAGGATGACGATG</named-content>-3’ </p> </list-item> <list-item> <p>dtSARM1-dN-R: 5’-<named-content content-type="sequence">ATAGCGGCCGCTTAGGTTGGACCCA</named-content>-3’</p> </list-item></list></sec><sec id="s4-20"><title>Western blots</title><p>Cells were lysed with RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA and 0.05% Triton, pH 7.4). Each sample was loaded onto 10–12% SDS-PAGE gels and the proteins were then transferred to a PVDF membranes. The membranes were blocked with 5% milk and blotted with anti-SARM1 (home-made), with anti-Tubulin (TransGen Biotech) as an internal control. After incubation with HRP-conjugated second antibodies, the signals were developed by ECL (Abvansta), detected, and quantified by a Chemidoc MP system and ImageLab software (Bio-Rad).</p></sec><sec id="s4-21"><title>Cryo-EM sample preparation, data collection, and processing</title><p>Pure dtSARM1-dN protein was concentrated to 3 mg/mL and pre-incubated with 50 μM dHNN at rt for 10 min, and applied to glow-discharged gold grid, blotted in FEI Vitrobot Mark IV (ThermoFisher Scientific) before frozen by liquid ethane and stored in liquid nitrogen. The sample without inhibitor was examined at the Cryo-EM center of Chinese University Hong Kong (Shenzhen) on a 300kV Titan Krios (ThermoFisher Scientific) equipped with Gatan K3 direct electron detector under magnification of 105,000x, with the corresponding pixel size of 0.85 Å. The dose rate was set to 17.6 e/pix/s and exposure time was set to 2.5 s to obtain 50 frames, which led to an accumulated dose of 61 electrons per Å<sup>2</sup>. The total dataset consists of 2692 raw movies with a defocus value range of −1.0 to −2.0 μm. Motion correction and CTF parameter estimation were performed with cryoSPARC (<xref ref-type="bibr" rid="bib33">Punjani et al., 2017</xref>). 2,012,198 particles were autopicked. After several rounds of 2D classification, 712,139 particles were selected for generation of the final 2D average results.</p><p>The dHNN-treated sample was examined at the Cryo-EM center of Southern University of Science and Technology on a Titan Krios G3 (ThermoFisher Scientific) with Gatan K2 summit detector with a nominal magnification of 130,000x and corresponding pixel size of 1.076 Å. A total accumulative dose of 50 e<sup>-</sup>/Å<sup>2</sup> was set for each exposure and split into 39 frames during data acquisition. The defocus range was set between −0.8 and −2.0 μm. In total, 2890 images were collected. Motion correction and CTF parameter estimation were performed with MotionCor2 and CTFFind4 built within Relion 3.1 (<xref ref-type="bibr" rid="bib7">Fernandez-Leiro and Scheres, 2017</xref>). After CTF estimation, images with thick ice, obvious shift or cleft were removed, which left 2673 images for further processing. 2,655,835 particles were autopicked from these images. After several rounds of 2D classification, 700,472 particles were selected and exported for generation of the final 2D average results with CryoSparc and 3D refinement with CisTEM beta-1.0.0 (<xref ref-type="bibr" rid="bib16">Grant et al., 2018</xref>). The particle stack was subject to 10 rounds of 3D auto-refinement among 6 classes using 6WPK as initial model. Four classes with higher estimated resolution were selected and combined for 20 more rounds of 3D manual global refinement and one class with the highest occupation (62.5%) and best resolution was chosen for several more rounds of 2D and 3D classification with Relion 3.1 and CisTEM beta-1.0.0. The resolution for the final map was around 2.4 Å.</p><p>The previously reported structures of the SARM1 SAM domain (PDB: 6O0S) and TIR domain (PDB: 6O0Q) were used as model templates during initial model building. The initial model of ARM domain was built de novo in Coot (<xref ref-type="bibr" rid="bib5">Emsley et al., 2010</xref>). The three domains of SARM1 were connected in Coot and docked into density maps using Dock in Map module of Phenix 1.16 (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>) with C8 symmetry and then subjected to multiple rounds of Real-space refinement in Phenix. The dHNN molecule was built and fitted into the density around Cys311 of the initial model in Coot. The final models were validated with Comprehensive Validation module of Phenix and the refinement statistics are listed in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The model and EM map have been deposited in Protein Data Bank with accession codes of PDB ID 7DJT and EMD-30700.</p></sec><sec id="s4-22"><title>Data analysis</title><p>All experiments contained at least three biological replicates. Data shown in each figure are all means ± SD. The unpaired Student’s <italic>t</italic>-test was used to determine statistical significance of differences between means (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001). GraphPad Prism 8.0 was used for data analysis.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We would like to thank the Cryo-EM center of Southern University of Science and Technology for Cryo-EM data collection and the HPC-Service Station in Cryo-EM center of Southern University of Science and Technology for data processing. We acknowledge Beijing Artivila Biopharma Co. Ltd for the supports.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Two Chinese patents (202010528147.3; 202011359354.7) are in the process of application.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Validation, Visualization</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was carried out in strict accordance with animal use protocol approved by Peking University Shenzhen Graduate School Animal Care and Use Committee (#AP0015001). All animals (C57BL6/J), purchased from Guangdong Medical Laboratory Animal Center (China), were handled in accordance with the guidelines of the Committee on the Ethic of Animal Experiments. All surgery was performed after euthanasia and efforts were made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Refinement statistics for the SAMR1-dHNN structure.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67381-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67381-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Diffraction data have been deposited in PDB under the accession code 7DJT. All data generated or analysed during this study are included in the manuscript and supporting files.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Human SARM1 inhibitory state bounded with inhibitor dHNN</data-title><source>RCSB Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/7DJT">7DJT</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>PHENIX</italic>: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname> <given-names>VJ</given-names></name><name><surname>McNaughton</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Evaluation of nanobody conjugates and protein fusions as bioanalytical reagents</article-title><source>Analytical Chemistry</source><volume>89</volume><fpage>3819</fpage><lpage>3823</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b00470</pub-id><pub-id pub-id-type="pmid">28316235</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callan</surname> <given-names>HE</given-names></name><name><surname>Jenkins</surname> <given-names>RE</given-names></name><name><surname>Maggs</surname> <given-names>JL</given-names></name><name><surname>Lavergne</surname> <given-names>SN</given-names></name><name><surname>Clarke</surname> <given-names>SE</given-names></name><name><surname>Naisbitt</surname> <given-names>DJ</given-names></name><name><surname>Park</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation</article-title><source>Chemical Research in Toxicology</source><volume>22</volume><fpage>937</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1021/tx900034r</pub-id><pub-id pub-id-type="pmid">19358516</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname> <given-names>MP</given-names></name><name><surname>Höke</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Programmed axon degeneration: from mouse to mechanism to medicine</article-title><source>Nature Reviews Neuroscience</source><volume>21</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/s41583-020-0269-3</pub-id><pub-id pub-id-type="pmid">32152523</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Lohkamp</surname> <given-names>B</given-names></name><name><surname>Scott</surname> <given-names>WG</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of <italic>coot</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essuman</surname> <given-names>K</given-names></name><name><surname>Summers</surname> <given-names>DW</given-names></name><name><surname>Sasaki</surname> <given-names>Y</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The SARM1 toll/Interleukin-1 receptor domain possesses intrinsic NAD<sup>+</sup> Cleavage Activity that Promotes Pathological Axonal Degeneration</article-title><source>Neuron</source><volume>93</volume><fpage>1334</fpage><lpage>1343</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.02.022</pub-id><pub-id pub-id-type="pmid">28334607</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Leiro</surname> <given-names>R</given-names></name><name><surname>Scheres</surname> <given-names>SHW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A pipeline approach to single-particle processing in <italic>RELION</italic></article-title><source>Acta Crystallographica Section D Structural Biology</source><volume>73</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1107/S2059798316019276</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figley</surname> <given-names>MD</given-names></name><name><surname>Gu</surname> <given-names>W</given-names></name><name><surname>Nanson</surname> <given-names>JD</given-names></name><name><surname>Shi</surname> <given-names>Y</given-names></name><name><surname>Sasaki</surname> <given-names>Y</given-names></name><name><surname>Cunnea</surname> <given-names>K</given-names></name><name><surname>Malde</surname> <given-names>AK</given-names></name><name><surname>Jia</surname> <given-names>X</given-names></name><name><surname>Luo</surname> <given-names>Z</given-names></name><name><surname>Saikot</surname> <given-names>FK</given-names></name><name><surname>Mosaiab</surname> <given-names>T</given-names></name><name><surname>Masic</surname> <given-names>V</given-names></name><name><surname>Holt</surname> <given-names>S</given-names></name><name><surname>Hartley-Tassell</surname> <given-names>L</given-names></name><name><surname>McGuinness</surname> <given-names>HY</given-names></name><name><surname>Manik</surname> <given-names>MK</given-names></name><name><surname>Bosanac</surname> <given-names>T</given-names></name><name><surname>Landsberg</surname> <given-names>MJ</given-names></name><name><surname>Kerry</surname> <given-names>PS</given-names></name><name><surname>Mobli</surname> <given-names>M</given-names></name><name><surname>Hughes</surname> <given-names>RO</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name><name><surname>Kobe</surname> <given-names>B</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Ve</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARM1 is a metabolic sensor activated by an increased NMN/NAD<sup>+</sup> ratio to trigger axon degeneration</article-title><source>Neuron</source><volume>109</volume><fpage>1118</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.02.009</pub-id><pub-id pub-id-type="pmid">33657413</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname> <given-names>DP</given-names></name><name><surname>Kiyota</surname> <given-names>T</given-names></name><name><surname>Dong</surname> <given-names>Y</given-names></name><name><surname>Ikezu</surname> <given-names>T</given-names></name><name><surname>Vennerstrom</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers</article-title><source>Journal of Medicinal Chemistry</source><volume>53</volume><fpage>7992</fpage><lpage>7999</lpage><pub-id pub-id-type="doi">10.1021/jm1006929</pub-id><pub-id pub-id-type="pmid">21038854</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galione</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Cyclic ADP-ribose, the ADP-ribosyl cyclase pathway and calcium signalling</article-title><source>Molecular and Cellular Endocrinology</source><volume>98</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/0303-7207(94)90130-9</pub-id><pub-id pub-id-type="pmid">8143921</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname> <given-names>S</given-names></name><name><surname>Doan</surname> <given-names>RA</given-names></name><name><surname>Strickland</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice</article-title><source>Brain</source><volume>139</volume><fpage>3092</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1093/brain/aww251</pub-id><pub-id pub-id-type="pmid">27797810</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerdts</surname> <given-names>J</given-names></name><name><surname>Summers</surname> <given-names>DW</given-names></name><name><surname>Sasaki</surname> <given-names>Y</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sarm1-mediated axon degeneration requires both SAM and TIR interactions</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>13569</fpage><lpage>13580</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1197-13.2013</pub-id><pub-id pub-id-type="pmid">23946415</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graeff</surname> <given-names>RM</given-names></name><name><surname>Walseth</surname> <given-names>TF</given-names></name><name><surname>Fryxell</surname> <given-names>K</given-names></name><name><surname>Branton</surname> <given-names>WD</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Enzymatic synthesis and characterizations of cyclic GDP-ribose A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity</article-title><source>Journal of Biological Chemistry</source><volume>269</volume><fpage>30260</fpage><lpage>30267</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)43806-9</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graeff</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Kriksunov</surname> <given-names>IA</given-names></name><name><surname>Hao</surname> <given-names>Q</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine nicotinic acid adenine dinucleotide phosphate (NAADP) Synthesis and hydrolysis activities</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>28951</fpage><lpage>28957</lpage><pub-id pub-id-type="doi">10.1074/jbc.M604370200</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graeff</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity</article-title><source>Biochemical Journal</source><volume>361</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1042/bj3610379</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname> <given-names>T</given-names></name><name><surname>Rohou</surname> <given-names>A</given-names></name><name><surname>Grigorieff</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>cisTEM, user-friendly software for single-particle image processing</article-title><source>eLife</source><volume>7</volume><elocation-id>e35383</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.35383</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname> <given-names>RO</given-names></name><name><surname>Bosanac</surname> <given-names>T</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>Engber</surname> <given-names>TM</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name><name><surname>Devraj</surname> <given-names>R</given-names></name><name><surname>Krauss</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Small molecule SARM1 inhibitors recapitulate the SARM1<sup>-/-</sup> Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108588</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108588</pub-id><pub-id pub-id-type="pmid">33406435</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>CH</given-names></name><name><surname>Chang</surname> <given-names>Q</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The NAD<sup>+</sup>-mediated self-inhibition mechanism of pro-neurodegenerative SARM1</article-title><source>Nature</source><volume>588</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2862-z</pub-id><pub-id pub-id-type="pmid">33053563</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolvari</surname> <given-names>E</given-names></name><name><surname>Amoozadeh</surname> <given-names>A</given-names></name><name><surname>Koukabi</surname> <given-names>N</given-names></name><name><surname>Otokesh</surname> <given-names>S</given-names></name><name><surname>Isari</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Aryl diazonium nanomagnetic sulfate and potassium iodide: an iodination process</article-title><source>Tetrahedron Letters</source><volume>55</volume><fpage>3648</fpage><lpage>3651</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2014.02.073</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lator</surname> <given-names>A</given-names></name><name><surname>Gaillard</surname> <given-names>S</given-names></name><name><surname>Poater</surname> <given-names>A</given-names></name><name><surname>Renaud</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Well-Defined Phosphine-Free Iron-Catalyzed <italic>N</italic>-Ethylation and <italic>N</italic>-Methylation of amines with ethanol and methanol</article-title><source>Organic Letters</source><volume>20</volume><fpage>5985</fpage><lpage>5990</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.8b02080</pub-id><pub-id pub-id-type="pmid">30234993</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as Messengers for Calcium Mobilization</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>31633</fpage><lpage>31640</lpage><pub-id pub-id-type="doi">10.1074/jbc.R112.349464</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>HC</given-names></name><name><surname>Aarhus</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Structural determinants of nicotinic acid adenine dinucleotide phosphate important for its Calcium-mobilizing activity</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><fpage>20378</fpage><lpage>20383</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.33.20378</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>HC</given-names></name><name><surname>Zhao</surname> <given-names>YJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resolving the topological enigma in Ca2+ signaling by cyclic ADP-ribose and NAADP</article-title><source>Journal of Biological Chemistry</source><volume>294</volume><fpage>19831</fpage><lpage>19843</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV119.009635</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemercier</surname> <given-names>G</given-names></name><name><surname>Martineau</surname> <given-names>C</given-names></name><name><surname>Mulatier</surname> <given-names>J-C</given-names></name><name><surname>Wang</surname> <given-names>I</given-names></name><name><surname>Stéphan</surname> <given-names>O</given-names></name><name><surname>Baldeck</surname> <given-names>P</given-names></name><name><surname>Andraud</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Analogs of Michler’s ketone for two-photon absorption initiation of polymerization in the near infrared: synthesis and photophysical properties</article-title><source>New J. Chem.</source><volume>30</volume><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1039/B608391A</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>YJ</given-names></name><name><surname>Li</surname> <given-names>WH</given-names></name><name><surname>Hou</surname> <given-names>YN</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Zhao</surname> <given-names>ZY</given-names></name><name><surname>Fang</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>SL</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels</article-title><source>PNAS</source><volume>114</volume><fpage>8283</fpage><lpage>8288</lpage><pub-id pub-id-type="doi">10.1073/pnas.1703718114</pub-id><pub-id pub-id-type="pmid">28720704</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loring</surname> <given-names>HS</given-names></name><name><surname>Parelkar</surname> <given-names>SS</given-names></name><name><surname>Mondal</surname> <given-names>S</given-names></name><name><surname>Thompson</surname> <given-names>PR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of the first noncompetitive SARM1 inhibitors</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>28</volume><elocation-id>115644</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmc.2020.115644</pub-id><pub-id pub-id-type="pmid">32828421</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marinkovic</surname> <given-names>VD</given-names></name><name><surname>Agbaba</surname> <given-names>D</given-names></name><name><surname>Karljikovic-Rajic</surname> <given-names>K</given-names></name><name><surname>Vladimirov</surname> <given-names>S</given-names></name><name><surname>Nedeljkovic</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Photochemical degradation of solid-state nisoldipine monitored by HPLC</article-title><source>Journal of Pharmaceutical and Biomedical Analysis</source><volume>32</volume><fpage>929</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(03)00194-8</pub-id><pub-id pub-id-type="pmid">12899979</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Möller</surname> <given-names>C</given-names></name><name><surname>Davis</surname> <given-names>WC</given-names></name><name><surname>Thompson</surname> <given-names>VR</given-names></name><name><surname>Marí</surname> <given-names>F</given-names></name><name><surname>DeCaprio</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Proteomic analysis of thiol modifications and assessment of structural changes in hemoglobin induced by the aniline metabolites N-Phenylhydroxylamine and nitrosobenzene</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>14794</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-14653-w</pub-id><pub-id pub-id-type="pmid">29093547</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munshi</surname> <given-names>CB</given-names></name><name><surname>Fryxell</surname> <given-names>KB</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name><name><surname>Branton</surname> <given-names>WD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Large-scale production of human CD38 in yeast by fermentation</article-title><source>Methods in Enzymology</source><volume>280</volume><fpage>318</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/s0076-6879(97)80123-1</pub-id><pub-id pub-id-type="pmid">9211327</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname> <given-names>S</given-names></name><name><surname>Wei</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Qiu</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Hu</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>M</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Mao</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Lan</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Novel inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate <italic>Staphylococcus aureus</italic> infections in vivo</article-title><source>Journal of Medicinal Chemistry</source><volume>60</volume><fpage>8145</fpage><lpage>8159</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00949</pub-id><pub-id pub-id-type="pmid">28880552</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterloh</surname> <given-names>JM</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Rooney</surname> <given-names>TM</given-names></name><name><surname>Fox</surname> <given-names>AN</given-names></name><name><surname>Adalbert</surname> <given-names>R</given-names></name><name><surname>Powell</surname> <given-names>EH</given-names></name><name><surname>Sheehan</surname> <given-names>AE</given-names></name><name><surname>Avery</surname> <given-names>MA</given-names></name><name><surname>Hackett</surname> <given-names>R</given-names></name><name><surname>Logan</surname> <given-names>MA</given-names></name><name><surname>MacDonald</surname> <given-names>JM</given-names></name><name><surname>Ziegenfuss</surname> <given-names>JS</given-names></name><name><surname>Milde</surname> <given-names>S</given-names></name><name><surname>Hou</surname> <given-names>YJ</given-names></name><name><surname>Nathan</surname> <given-names>C</given-names></name><name><surname>Ding</surname> <given-names>A</given-names></name><name><surname>Brown</surname> <given-names>RH</given-names></name><name><surname>Conforti</surname> <given-names>L</given-names></name><name><surname>Coleman</surname> <given-names>M</given-names></name><name><surname>Tessier-Lavigne</surname> <given-names>M</given-names></name><name><surname>Züchner</surname> <given-names>S</given-names></name><name><surname>Freeman</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>dSarm/Sarm1 is required for activation of an injury-induced axon death pathway</article-title><source>Science</source><volume>337</volume><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1126/science.1223899</pub-id><pub-id pub-id-type="pmid">22678360</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlicki</surname> <given-names>M</given-names></name><name><surname>Collins</surname> <given-names>HA</given-names></name><name><surname>Denning</surname> <given-names>RG</given-names></name><name><surname>Anderson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Two-photon absorption and the design of two-photon dyes</article-title><source>Angewandte Chemie International Edition</source><volume>48</volume><fpage>3244</fpage><lpage>3266</lpage><pub-id pub-id-type="doi">10.1002/anie.200805257</pub-id><pub-id pub-id-type="pmid">19370705</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punjani</surname> <given-names>A</given-names></name><name><surname>Rubinstein</surname> <given-names>JL</given-names></name><name><surname>Fleet</surname> <given-names>DJ</given-names></name><name><surname>Brubaker</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination</article-title><source>Nature Methods</source><volume>14</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4169</pub-id><pub-id pub-id-type="pmid">28165473</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname> <given-names>Y</given-names></name><name><surname>Nakagawa</surname> <given-names>T</given-names></name><name><surname>Mao</surname> <given-names>X</given-names></name><name><surname>DiAntonio</surname> <given-names>A</given-names></name><name><surname>Milbrandt</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD<sup>+</sup> depletion</article-title><source>eLife</source><volume>5</volume><elocation-id>e19749</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.19749</pub-id><pub-id pub-id-type="pmid">27735788</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname> <given-names>FH</given-names></name><name><surname>Menzies</surname> <given-names>FM</given-names></name><name><surname>Lopez</surname> <given-names>A</given-names></name><name><surname>Stamatakou</surname> <given-names>E</given-names></name><name><surname>Karabiyik</surname> <given-names>C</given-names></name><name><surname>Ureshino</surname> <given-names>R</given-names></name><name><surname>Ricketts</surname> <given-names>T</given-names></name><name><surname>Jimenez-Sanchez</surname> <given-names>M</given-names></name><name><surname>Esteban</surname> <given-names>MA</given-names></name><name><surname>Lai</surname> <given-names>L</given-names></name><name><surname>Tortorella</surname> <given-names>MD</given-names></name><name><surname>Luo</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Metzakopian</surname> <given-names>E</given-names></name><name><surname>Fernandes</surname> <given-names>HJR</given-names></name><name><surname>Bassett</surname> <given-names>A</given-names></name><name><surname>Karran</surname> <given-names>E</given-names></name><name><surname>Miller</surname> <given-names>BL</given-names></name><name><surname>Fleming</surname> <given-names>A</given-names></name><name><surname>Rubinsztein</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1817</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09494-2</pub-id><pub-id pub-id-type="pmid">31000720</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporny</surname> <given-names>M</given-names></name><name><surname>Guez-Haddad</surname> <given-names>J</given-names></name><name><surname>Khazma</surname> <given-names>T</given-names></name><name><surname>Yaron</surname> <given-names>A</given-names></name><name><surname>Dessau</surname> <given-names>M</given-names></name><name><surname>Shkolnisky</surname> <given-names>Y</given-names></name><name><surname>Mim</surname> <given-names>C</given-names></name><name><surname>Isupov</surname> <given-names>MN</given-names></name><name><surname>Zalk</surname> <given-names>R</given-names></name><name><surname>Hons</surname> <given-names>M</given-names></name><name><surname>Opatowsky</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for SARM1 inhibition and activation under energetic stress</article-title><source>eLife</source><volume>9</volume><elocation-id>e62021</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.62021</pub-id><pub-id pub-id-type="pmid">33185189</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkiew</surname> <given-names>E</given-names></name><name><surname>Falconer</surname> <given-names>D</given-names></name><name><surname>Reed</surname> <given-names>N</given-names></name><name><surname>Höke</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy</article-title><source>Journal of the Peripheral Nervous System</source><volume>22</volume><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1111/jns.12219</pub-id><pub-id pub-id-type="pmid">28485482</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>YJ</given-names></name><name><surname>Lam</surname> <given-names>CM</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The membrane-bound enzyme CD38 exists in two opposing orientations</article-title><source>Science Signaling</source><volume>5</volume><elocation-id>ra67</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2002700</pub-id><pub-id pub-id-type="pmid">22969159</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>ZY</given-names></name><name><surname>Xie</surname> <given-names>XJ</given-names></name><name><surname>Li</surname> <given-names>WH</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>SL</given-names></name><name><surname>Lu</surname> <given-names>JG</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>LH</given-names></name><name><surname>Xu</surname> <given-names>Z</given-names></name><name><surname>Lee</surname> <given-names>HC</given-names></name><name><surname>Zhao</surname> <given-names>YJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Cell-Permeant mimetic of NMN activates SARM1 to produce cyclic ADP-Ribose and induce Non-apoptotic cell death</article-title><source>iScience</source><volume>15</volume><fpage>452</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2019.05.001</pub-id><pub-id pub-id-type="pmid">31128467</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67381.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lin</surname><given-names>Hening</given-names></name><role>Reviewing Editor</role><aff><institution>Cornell University</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Lin</surname><given-names>Hening</given-names> </name><role>Reviewer</role><aff><institution>Cornell University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is a very nice manuscript describing the development of small molecule probes that can detect the activity of SARM1 in live cells. One of the probe allows the author to monitor the activity SARM1 and discovery a small molecule derived from an hyertension drug as an effective SARM1 inhibitor. SARM1 is an enzyme that can convert NAD+ to ADP-ribose or cyclic ADP-ribose and is implicated in axon degeneration, thus the probe and the inhibitor described in the manuscript could lead to future therapeutic development targeting SARM1 to treat axon degeneration.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Permeant Fluorescent Probes Visualize the Activation of SARM1 and Uncover an Anti-neurodegenerative Drug Candidate&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Hening Lin as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Michael Marletta as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Since the inhibitors react with multiple cysteines and the mechanism of inactivation is not clear from the MS data, please either propose a reasonable mechanism and/or minimize those aspects of the report and explicitly state that the inhibitor modifies multiple cysteines and is unlikely to be a very useful probe.</p><p>2. It would be necessary to do a more thorough editing and proof-reading to further improve the language.</p><p><italic>Reviewer #1:</italic></p><p>The authors aimed to develop cell-permeable small molecule probes that can monitor the activity of SARM1, an enzyme that hydrolyzes NAD+ and is thought to be important for axon degeneration. They successfully achieved this goal using the base exchange activity of SARM1 to make a donor-π-acceptor type of fluorophore. The best probe described in the manuscript is PC6. A number of experiments were carried to rigorously test that the probe works as expected. PC6 has a number of nice features. It is cell permeable, gives much stronger signal than any other probes known for SARM1, is specific for SARM1 and does not detect the activity of CD38 (another enzyme that has similar activity), and allows detection of endogenous SARM1 activation in neurons.</p><p>Using this probe PC6, the authors was able to monitor SARM1 activity in neurons treated with vincristine and demonstrated that SARM1 activation precedes axon degeneration and is important but not sufficient for axon degeneration. Most importantly, using this probe to monitor SARM activity, they screened a library of about 2000 drug molecules and discovered that a hypertension drug, nisoldipine, could inhibits SARM1. Surprisingly, further studies showed that a derivative of nisoldipine, dehydronitrosonisoldipine (dHNN, present in the nisoldipine compound used ), is actually the inhibitor of SARM1. They then carried nice mechanistic studies (including mass spectrometry and cryo-EM structures) showing that dHNN inhibits SARM1 by covalently modify Cys311 residue in the ARM domain. The dHNN binding site is similar to the previously established NAD+ inhibitory site.</p><p>Overall, the probe is novel with many useful features, the study is rigorous and rather complete, and the conclusion is well supported. I believe the study will be important for the field and will be well received by the field.</p><p><italic>Reviewer #2:</italic></p><p>The manuscript by Li et al. describes the development of styrylpyridines as cell permeant fluorescent sensors of SARM1 activity. This work is significant because SARM1 activity is increased during neuron damage and SARM1 knockout mice are protected from neuronal degeneration caused by a variety of physical and chemical insults. Thus, SARM1 is a key player in neuronal degeneration and a novel therapeutic target. SARM1 is an NAD+ hydrolase that cleaves NAD+ to form nicotinamide and ADP ribose (and to a small extent cyclic ADP ribose) via a reactive oxocarbenium intermediate. Notably, this intermediate can either react with water (hydrolysis), the adenosine ring (cyclization to cADPR), or with a pyridine containing molecule in a 'base-exchange reaction'. The styrylpyridines described by Li et al. exploit this base-exchange reaction; the styrylpyridines react with the intermediate to form a fluorescent product. Notably, the best probe (PC6) can be used to monitor SARM1 activity in vitro and in cells. Upon validating the utility of PC6, the authors use this compound to perform a high throughput screen of the Approved Drug Library (L1000) from TargetMol and identify nisoldipine as a hit. Further studies revealed that a minor metabolite, dehydronitrosonisoldipine (dHNN), is the true inhibitor, acting with single digit μM potency. The authors provide structural and proteomic data suggesting that dHNN inhibits SARM1 activity via the covalent modification of C311 which stabilizes the enzyme in the autoinhibited state.</p><p>Key strengths of the manuscript include the probe design and the authors demonstration that they can be used to monitor SARM1 activity in vitro in an HTS format and in cells. The identification of C311 as potential reactive cysteine that could be targeted for drug development is an important and significant insight.</p><p>Key weaknesses include the fact that dHNN is a highly reactive molecule and the authors note that it modifies multiple sites on the protein (they mentioned 8 but MS2 spectra for only 5 are provided). As such, the compound appears to be a non-specific alkylator that will have limited utility as a SARM1 inhibitor. Additionally, no information is provided on the proteome-wide selectivity of the compound. An additional key weakness is the lack of any mechanistic insights into how the adducts are generated.</p><p>Moreover, it is not clear how the proposed sulphonamide and thiohydroxylamine adducts are formed. From the images presented, it is unclear whether there is sufficient 'density' in the cryoEM maps to accurately predict the sites of modification. Finally, the authors do not show whether the conversion of PC6 to PAD6 is stable or if PAD6 can also be hydrolyzed to form ADPR.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67381.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Since the inhibitors react with multiple cysteines and the mechanism of inactivation is not clear from the MS data, please either propose a reasonable mechanism and/or minimize those aspects of the report and explicitly state that the inhibitor modifies multiple cysteines and is unlikely to be a very useful probe.</p></disp-quote><p>Although dHNN may react with multiple cysteines, our results indicate the primary one is Cys311. Nevertheless, we have added the qualification that other Cys may contribute to the inhibition (c.f. Abstract, the second paragraph on p.17). The evidence for Cys311 being dominant includes quantification of the intensity of the modified peptides and normalizing with that of the corresponding total peptides, with or without modification, showing that the modification is mainly on Cys311 (Figure 5—figure supplement 1). The dominant role of Cys311 is also confirmed by our mutagenesis and structural studies. Furthermore, quantification of cysteine-containing peptides of other proteins showed no dHNN modification. So, we conclude that dHNN shows significant specificity to the Cys311 of SARM1. The inhibitory mechanism of dHHN we propose is like that of NAD, prohibiting the conformational change of the ARM domain by acting on the allosteric site that includes Cys311 to inhibit the activation of SARM1.</p><disp-quote content-type="editor-comment"><p>2. It would be necessary to do a more thorough editing and proof-reading to further improve the language.</p></disp-quote><p>We have carefully edited and improved our manuscript throughout.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>The manuscript by Li et al. describes the development of styrylpyridines as cell permeant fluorescent sensors of SARM1 activity. This work is significant because SARM1 activity is increased during neuron damage and SARM1 knockout mice are protected from neuronal degeneration caused by a variety of physical and chemical insults. Thus, SARM1 is a key player in neuronal degeneration and a novel therapeutic target. SARM1 is an NAD+ hydrolase that cleaves NAD+ to form nicotinamide and ADP ribose (and to a small extent cyclic ADP ribose) via a reactive oxocarbenium intermediate. Notably, this intermediate can either react with water (hydrolysis), the adenosine ring (cyclization to cADPR), or with a pyridine containing molecule in a 'base-exchange reaction'. The styrylpyridines described by Li et al. exploit this base-exchange reaction; the styrylpyridines react with the intermediate to form a fluorescent product. Notably, the best probe (PC6) can be used to monitor SARM1 activity in vitro and in cells. Upon validating the utility of PC6, the authors use this compound to perform a high throughput screen of the Approved Drug Library (L1000) from TargetMol and identify nisoldipine as a hit. Further studies revealed that a minor metabolite, dehydronitrosonisoldipine (dHNN), is the true inhibitor, acting with single digit μM potency. The authors provide structural and proteomic data suggesting that dHNN inhibits SARM1 activity via the covalent modification of C311 which stabilizes the enzyme in the autoinhibited state.</p><p>Key strengths of the manuscript include the probe design and the authors demonstration that they can be used to monitor SARM1 activity in vitro in an HTS format and in cells. The identification of C311 as potential reactive cysteine that could be targeted for drug development is an important and significant insight.</p><p>Key weaknesses include the fact that dHNN is a highly reactive molecule and the authors note that it modifies multiple sites on the protein (they mentioned 8 but MS2 spectra for only 5 are provided). As such, the compound appears to be a non-specific alkylator that will have limited utility as a SARM1 inhibitor. Additionally, no information is provided on the proteome-wide selectivity of the compound.</p></disp-quote><p>Although dHNN may react with cysteines in general, our results indicate it does target specifically Cys311. Quantification of cysteine-containing peptides of other proteins showed no dHNN modification. So, we conclude that dHNN shows significant specificity to the Cys311 of SARM1. Some other SH-reactive agents we tested show little inhibition on SARM1. The evidence for Cys311 being dominant includes quantification of the intensity of the modified peptides and normalizing with that of the corresponding total peptides, with or without modification, showing that the modification is mainly on Cys311 (Figure 5—figure supplement 1). The dominant role of Cys311 is also confirmed by our mutagenesis and structural studies. Our result strongly suggested that the C311 is a druggable site for designing allosteric inhibitors against SARM1 activation.</p><p>dHNN is effective in inhibiting SARM1 activation and AxD at low μM range, making it a useful inhibitor. Considering that the neuroprotective effect of NSDP, an approved drug, may well be due to dHNN, labeling it as inhibitor of SARM1 serves focus more attentions.</p><p>Revision has been made in Discussion.</p><disp-quote content-type="editor-comment"><p>An additional key weakness is the lack of any mechanistic insights into how the adducts are generated. Moreover, it is not clear how the proposed sulphonamide and thiohydroxylamine adducts are formed.</p></disp-quote><p>Please refer to Figure 1 in the paper (Sci Rep. 2017 Nov 1;7(1):14794.), which has been cited in our manuscript.</p><disp-quote content-type="editor-comment"><p>From the images presented, it is unclear whether there is sufficient 'density' in the cryoEM maps to accurately predict the sites of modification.</p></disp-quote><p>Please refer to Figure 5F, in which we show the close-up view of dHNN in the ARM domain. dHNN (purple) linked to the residue C311 and formed the hydrophobic interactions with surrounding residues E264, L268, R307, F308, and A315. The extra electron densities near the residue C311 fit the shape of dHNN and were shown as grey mesh.</p><disp-quote content-type="editor-comment"><p>Finally, the authors do not show whether the conversion of PC6 to PAD6 is stable or if PAD6 can also be hydrolyzed to form ADPR.</p></disp-quote><p>PAD6 is stable and cannot be hydrolyzed by the activated SARM1, as shown in <xref ref-type="fig" rid="respfig1">Author response image 1</xref>. The reactions contain 10μM PAD6, 100 μM NMN, 2.65 μg/mL SARM1 or blank as a control. The PAD6 fluorescence was monitored for one hour and did not change in both groups.</p><fig id="respfig1"><label>Author response image 1.</label><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67381-resp-fig1-v2.tif"/></fig></body></sub-article></article>